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Spinal and bulbar muscular atrophy (SBMA, Kennedy’s disease), a late-onset neuromuscu-
lar disorder, is caused by expansion of the polymorphic polyglutamine tract in the androgen
receptor (AR).The AR is a ligand-activated transcription factor, but plays roles in other cellu-
lar pathways. In SBMA, selective motor neuron degeneration occurs in the brainstem and
spinal cord, thus the causes of neuronal dysfunction have been studied. However, path-
ogenic pathways in muscles may also be involved. Cultured cells, fly and mouse models
are used to study the molecular mechanisms leading to SBMA. Both the structure of the
polyglutamine-expanded AR (polyQ AR) and its interactions with other proteins are altered
relative to the normal AR.The ligand-dependent translocation of the polyQ AR to the nucleus
appears to be critical, as are interdomain interactions.The polyQ AR, or fragments thereof,
can form nuclear inclusions, but their pathogenic or protective nature is unclear. Other data
suggests soluble polyQ AR oligomers can be harmful. Post-translational modifications such
as phosphorylation, acetylation, and ubiquitination influence AR function and modulate the
deleterious effects of the polyQ AR. Transcriptional dysregulation is highly likely to be a
factor in SBMA; deregulation of non-genomic AR signaling may also be involved. Studies
on polyQ AR-protein degradation suggest inhibition of the ubiquitin proteasome system
and changes to autophagic pathways may be relevant. Mitochondrial function and axonal
transport may also be affected by the polyQ AR. Androgens, acting through the AR, can
be neurotrophic and are important in muscle development; hence both loss of normal AR
functions and gain of novel harmful functions by the polyQ AR can contribute to neurode-
generation and muscular atrophy. Thus investigations into polyQ AR function have shown
that multiple complex mechanisms lead to the initiation and progression of SBMA.
Keywords: androgen receptor, spinal and bulbar muscular atrophy, Kennedy’s disease, polyglutamine disease,
neuromuscular disorder, mouse models, loss-of-function, gain-of-function
INTRODUCTION
Genetic alterations in the X-linked androgen receptor (AR) gene
are associated with spinal and bulbar muscular atrophy (SBMA,
Kennedy’s disease), an adult-onset neuromuscular disease, andro-
gen insensitivity syndrome (AIS), and prostate cancer (Gottlieb
et al., 2004, 2012). Although AR point mutations, insertions, and
deletions lead to varying degrees of AIS, the underlying cause of
SBMA is an expansion of the polymorphic AR CAG repeat encod-
ing a glutamine tract (La Spada et al., 1991). As a result, the AR
protein contains an expanded polyglutamine tract (n≥ 38) that
alters the AR’s normal functions and physiological roles. This arti-
cle refers to the polyglutamine-expanded AR as the polyQ AR,
in order to differentiate it from mutant ARs found in other dis-
eases, and primarily focuses on investigations into the molecular
pathogenesis of SBMA published since our last review (Beitel et al.,
2005).
SBMA is one of at least nine neurodegenerative dis-
eases caused by expansion of a polyglutamine tract within
a specific protein. Others include Huntington’s disease (HD),
dentatorubral-pallidoluysian atrophy (DRPLA), and six spin-
ocerebellar ataxias [SCA1, SCA2, SCA3 (Machado-Joseph disease),
SCA-6, SCA-7, SCA-17 (Truant et al., 2006; Orr and Zoghbi, 2007;
La Spada and Taylor, 2010)]. Except for SBMA, which is X-linked,
these disorders are inherited in an autosomal-dominant fashion.
SBMA has a prevalence of about 1 in 50,000 males, HD, 1 per
15,000 persons worldwide, and, all together, the prevalence of the
SCAs has been estimated at∼3 per 100,000 (Guyenet and La Spada,
2006; Truant et al., 2006). The polyglutamine diseases share sev-
eral features including late-onset, progressive neurodegeneration,
accumulation of misfolded polyQ proteins in the cytoplasm or
nucleus of neurons, and a positive correlation between CAG repeat
length and disease severity (Parodi and Pennuto, 2011; Tanaka
et al., 2012). Despite widespread expression of the polyQ proteins,
only specific neuronal populations are affected in each disease.
Even so, common mechanisms that disturb neuronal functions in
the polyQ disorders may be identified, leading to the development
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of effective therapies for these diseases (Pennuto and Fischbeck,
2010; Takahashi et al., 2010).
ANDROGEN RECEPTOR STRUCTURE AND MECHANISMS OF
ACTION
The AR is a member of the nuclear receptor superfamily and has
been well characterized as a ligand-activated transcription fac-
tor (Brinkmann, 2011). It contains an N-terminal domain (NTD)
that modulates transcriptional activation, a central DNA-binding
domain (DBD) that binds androgen-response elements (AREs),
and a C-terminal ligand-binding domain (LBD) (Figure 1). Sub-
domains involved in nuclear localization, dimerization, and inter-
action with heat-shock proteins (HSPs), co-activators, and other
proteins have also been identified (Centenera et al., 2008; Parodi
and Pennuto, 2011). Typically, the AR resides in the cytoplasm
of the cell in the absence of androgens, complexed with HSP
(Brinkmann, 2011). Once the receptor binds testosterone, or its
metabolite, 5α-dihydrotestosterone (DHT), the AR undergoes a
conformational change that promotes heat-shock protein disso-
ciation, and exposes its nuclear localization signal (NLS), DNA-
binding, and dimerization domains. Following nuclear transloca-
tion, ARs dimerize at AREs, recruit coregulators, and transactivate
AR target genes. The resulting ligand-dependent changes in mRNA
and protein expression are thought to be responsible for the differ-
ential physiological actions of testosterone and DHT (Brinkmann,
2011). However, a proteomics/systems biology approach to iden-
tifying proteins within AR complexes found that the wild-type AR
(wt AR) interacts with a wide variety of proteins involved in RNA
splicing, protein translation, proteasome/protein ubiquitination,
and transcription, suggesting the AR participates in numerous
cellular pathways (Paliouras et al., 2011).
ANDROGEN INSENSITIVITY SYNDROME AND SBMA
The AR plays a role in male sexual differentiation, and the devel-
opment and function of nerves, brain, testes, prostate, and muscles
(Jordan and Doncarlos, 2008; MacLean et al., 2008). In XY individ-
uals, the spectrum of AIS ranges from complete androgen insen-
sitivity, which results in a female phenotype, to mild resistance
to androgens, which leads to undervirilization, breast enlarge-
ment (gynecomastia), and/or infertility in males (Brinkmann,
2001). Conversely, men with SBMA generally develop an adult-
onset disorder with progressive muscle cramps, muscle weak-
ness and wasting, muscle twitching (fasciculations), dysarthria
(difficulty articulating), and dysphagia (difficulty swallowing)
(Rhodes et al., 2009; Katsuno et al., 2010b), in addition to signs
of mild AIS. In some cases, these patients are initially misdi-
agnosed with amyotrophic lateral sclerosis (ALS; Lou Gehrig’s
disease), however, genetic testing for an expanded AR CAG
repeat (n≥ 38) confirms a diagnosis of SBMA (Parboosingh
et al., 1997; Bruson et al., 2012). This differential diagnosis is
critical, as ∼50% of ALS patients die within 3 years of disease
onset, with involvement of both upper and lower motor neu-
rons (Mitchell and Borasio, 2007), whereas the life expectancy
for SBMA patients is normal or only minimally reduced (Chahin
et al., 2008).
Although men with SBMA may exhibit certain symptoms of
AIS [e.g., gynecomastia and reduced fertility (Dejager et al., 2002)],
which have been attributed to AR loss-of-function, individuals
with AIS do not display the neuromuscular phenotype associ-
ated with SBMA. Therefore, the polyQ AR must also gain novel
functions that are selectively harmful to motor neurons (Trifiro
et al., 1994), and, as shown recently, detrimental to skeletal mus-
cles. SBMA is characterized by loss of lower motor neurons from
the brain stem and anterior horn of the spinal cord, which has
been presumed to lead to progressive muscle wasting (Ross, 1995).
Accordingly, extensive research has focused on mechanisms by
which the polyQ AR causes neuronal dysfunction and degener-
ation (Walcott and Merry, 2002; Beitel et al., 2005; Cary and La
Spada, 2008; Finsterer, 2009), and, more recently, pathogenic path-
ways in muscles (Yu et al., 2006a; Monks et al., 2007; Palazzolo et al.,
2009). SBMA is unique among the polyglutamine diseases in that
it is a ligand (androgen)-dependent disorder (Katsuno et al., 2002;
Orr and Zoghbi, 2007). Thus, men expressing the polyQ AR exhibit
progressive neuromuscular signs, while women who are heterozy-
gous for the polyQ AR mutation develop very mild symptoms
due to and lower levels of circulating AR ligands (testosterone and
FIGURE 1 | Androgen receptor structure and post-translational
modifications. The locations of the AR N-terminal domain (NTD),
polyglutamine tract (polyQ), DNA-binding domain (DBD), hinge region, and
C-terminal ligand-binding domain (LBD) are shown. Phosphorylation can occur
on serine (S), threonine (T), and tyrosine (Y) residues. Specific lysine (K)
residues can be acetylated, ubiquitinated, sumoylated, or methylated as
indicated. Note the amino acid numbering is based on a 920 amino acid AR
(NCBI Reference Sequence: NM_000044.3) (Gottlieb et al., 2012).
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Table 1 | Cell and animal models of SBMA.
Cell line Description Features Reference
HEK293 Human embryonic kidney cells
HeLa Human cervical cancer cells
MN AR24; MN AR65 Mouse hybrid motoneuron-neuroblastoma
cells
MN-1 cells stably transfected with hAR 24Q or 65Q Brooks et al. (1997)
NSC34 Mouse neuroblastoma-spinal cord
hybrid cell line
Resemble developing motor neurons. Cashman et al.
(1992)
PC12 Rat adrenal pheochromocytoma-derived
cell line
Model system for neuronal differentiation Greene and Tischler
(1976)
SK-N-SH; SH-SY5Y Human neuroblastoma cell lines General neuron-like phenotype Ross et al. (1983)
Drosophila Description Features Reference
hAR(Q52) UAS-hAR(Q52); GMR-GAL4 ARQ52 expressed in eye photoreceptors neuron
under control of GMR promoter
Takeyama et al.
(2002)
ARQ77 UAS-ARQ77; ELAV-GAL4 ARQ77 expressed throughout CNS under control of
pan-neuronal ELAV promoter
Funderburk et al.
(2009)
ARQ65 pUAST-ARQ65; OK371-GAL4 ARQ65 expressed in a defined subset of neurons
under control of OK371 promoter
Jochum et al. (2012)
Mouse
model
AR/promoter Neuronal
pathology
Nuclear
inclusions
Muscle
pathology
Other features Reference
Transgenic AR120Q Full-length hAR (120Q); CMV
promoter
Yes No Yes Muscle weakness &
atrophy; testicular
atrophy
McManamny et al.
(2002)
Transgenic AR97Q Full-length hAR (97Q); chicken
β-actin promoter, CMV
enhancer
Yes Yes, motor
neurons, spinal
cord, CNS,
muscle, etc.
Yes Muscle weakness &
atrophy; neurogenic &
myogenic myopathy
Katsuno et al. (2002)
Transgenic AR100 Complete hAR gene (100Q) in
YAC
Yes No, motor
neurons; Yes,
CNS, liver, muscle
Yes Muscle weakness &
hindlimb atrophy
Sopher et al. (2004)
Transgenic AR112Q Full-length hAR (112Q); prion
protein promoter
No Yes, spinal cord,
brain stem &
cortex
No Hindlimb muscle
weakness; some male
infertility
Chevalier-Larsen
et al. (2004)
Knock-in AR113Q 1340 bp of mAR exon 1
replaced by hAR (113Q)
exon 1
Yes Yes, CNS, muscle Yes Motor deficits;
testicular atrophy
Albertelli et al.
(2006), Yu et al.
(2006a)
Transgenic HSA-AR Rat AR(22Q); HSA promoter Axonopathy No Yes Overexpress AR only in
skeletal muscle
Monks et al. (2007)
Tfm AR null No No No Model for AIS Gaspar et al. (1991)
CMV, cytomegalovirus; CNS, central nervous system; ELAV, embryonic lethal abnormal visual system promoter, hAR, human AR; HSA, human skeletal actin promoter;
mAR, mouse AR; YAC, yeast artificial chromosome.
DHT) (Chevalier-Larsen and Merry, 2012). SBMA has been found
in men from various ethnic backgrounds throughout the world,
although the prevalence is higher in certain regions of Japan and
Western Finland (Finsterer, 2010; Katsuno et al., 2010b).
MODEL SYSTEMS
A number of systems have been used to investigate the molec-
ular and cellular mechanisms underlying SBMA, ranging from
cultured cells to fly and mouse models [summarized in Table 1;
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mouse models reviewed in (Merry, 2005; Jordan and Lieberman,
2008; Figiel et al., 2012)]. Cells that lack AR are transiently or
stably transfected to examine the effects of the wt or polyQ AR.
PC12 cells that inducibly express wt and polyQ ARs have been
used extensively (e.g., Montie and Merry, 2009; Ranganathan et al.,
2009; Orr et al., 2010; Montie et al., 2011). In Drosophila, ARs can
be expressed in a tissue-specific fashion, depending on the pro-
moter used to drive AR expression. Most SBMA mouse models,
however, are based on overexpression of a polyQ AR protein with
more than 90Q; these mice also express endogenous wt AR (Kat-
suno et al., 2002; McManamny et al., 2002; Chevalier-Larsen et al.,
2004; Sopher et al., 2004). The transgenic AR97Q mice express the
full-length human AR (hAR) containing 97 CAG repeats under
the control of a cytomegalovirus enhancer and a chicken β-actin
promoter (Katsuno et al., 2002), while the prion protein promoter
was used to drive expression of the hAR with 112Q in the AR112Q
transgenic mice (Chevalier-Larsen et al., 2004). In contrast, a yeast
artificial chromosome (YAC) genomic fragment containing the
100 kb hAR gene with 100 CAG repeats was used to generate the
transgenic AR100 model mice (Sopher et al., 2004) (Table 1).
SBMA patients, however, express only a polyQ AR protein with
38–62 Gln, and lack wt AR. The presence of the wt AR in trans-
genic mice models may moderate or compensate for the effects of
the polyQ AR. This possibility was highlighted when the transgenic
AR100 YAC mice were crossed with AR null testicular feminiza-
tion mice (Tfm) (Table 1) (Thomas et al., 2006b), as the AR100Tfm
mice exhibited an accelerated neuromuscular disease phenotype
relative to the AR100 mice. As well, although the AR20 protein in
AR20Tfm mice was able to partially rescue the female-like Tfm
phenotype, the external genitalia of the AR100Tfm mice was the
same as female or androgen-insensitive Tfm mice, consistent with
a loss-of-function of the polyQ AR protein.
A knock-in mouse model for SBMA was made by replacing
1,340 bp of the coding sequence of mouse AR exon 1 with hAR
exon 1 sequence containing 113 CAGs (Albertelli et al., 2006; Yu
et al., 2006a) (Table 1). In contrast to the AR100Tfm mice, in
the transgenic AR113Q mice, the polyQ AR was able to effectively
masculinize the male mice, likely because the AR113Q is under the
regulatory control of the mouse AR gene promoter. The AR113Q
knock-in mice show signs of partial androgen insensitivity, includ-
ing testicular atrophy and decreased fertility, which are seen in
SBMA patients (Yu et al., 2006b). A striking age-dependent testic-
ular pathology was observed in the AR113Q, which was distinct
from the testicular atrophy seen in Tfm mice. These results lead to
the conclusion that the abnormalities in testicular morphology in
AR113Q were mediated not only by a partial loss of AR function,
but also reflect a“toxic”gain-of-function due to AR polyglutamine
tract expansion. Unexpectedly, transgenic mice that overexpress
the WT rat AR (22 Q) under control of the human skeletal α-actin
(HSA) promoter solely in their skeletal muscle fibers reproduced
many neuromuscular features of SBMA model mice (Monks et al.,
2007). The neuronal and muscular pathology, the localization of
nuclear inclusion and notable phenotype features of each mouse
model are summarize in Table 1.
Testosterone plays a crucial role in progression of symptoms in
SBMA mice models. However, raising testosterone levels in male
AR112Q transgenic mice for 6 months did not worsen severity
or age of onset of their disease, suggesting that the pathogenic
mechanism of disease in SBMA saturates at close to endogenous
testosterone levels (Chevalier-Larsen and Merry, 2012).
MECHANISMS CONTRIBUTING TO SBMA
Recent investigations have focused on a number of complex, and
not necessarily independent, mechanisms that lead to the devel-
opment of SBMA. These include alterations in AR structure,
interaction of the polyQ AR with other proteins, transcriptional
dysregulation, formation of harmful polyQ AR oligomers, changes
in post-translational modifications, loss of neurotrophic support,
and mitochondrial dysfunction. The possibility that polyQ AR
expression in skeletal muscles contributes to SBMA is intriguing.
More controversial are the role of nuclear inclusions, altered axonal
transport, and inhibition of the ubiquitin proteasome system.
These topics will be discussed in greater detail below.
ALTERATIONS IN AR STRUCTURE
Investigating polyglutamine repeats in their native context is
important for understanding their effects on protein structure
and function. In aqueous solution, purified recombinant wt AR
NTD (amino acids 1-537) had a relatively limited amount of sta-
ble secondary structure. However, for the AR-NTD45Q, a small,
but measureable increase in α-helix content and small decrease in
the β structures was noted (Davies et al., 2008). The AR-NTD45Q
peptide was more sensitive to urea-induced unfolding than the AR-
NTD20Q, and limited proteolysis, which was used as a probe for
global protein structure, generated a unique pattern of fragments
from the polyQ AR NTD. Thus, these spectroscopic and biochem-
ical analyses support the view that the expanded glutamine tract
alters the conformation of the AR NTD.
Structural analysis were also performed on full-length AR-
proteins expressed using the baculovirus-insect cell system
(Jochum et al., 2012). Atomic force microscopy was used to char-
acterize the sub-micrometer scale aggregates of the ARQ22 and
ARQ65 proteins purified from DHT-treated Sf9 cells (Jochum
et al., 2012). The wt AR formed annular oligomers 120–180 nm in
diameter, while the polyQ AR formed oligomeric fibrils up to 300–
600 nm in length. Interestingly, ARQ65 purified from DHT- and
melatonin-treated Sf9 cells produced annular oligomers,which did
not decrease human neuronal SK-N-SH cells viability, unlike the
fibrillar oligomer form, suggesting that AR structure modulates
pathogenicity.
INTERDOMAIN INTERACTIONS
Dynamic interactions between different AR domains are criti-
cal for the receptor’s function. DBD-mediated dimerization is
essential for the AR to bind DNA and regulate transcription (Cen-
tenera et al., 2008). Upon ligand-binding, the AR LBD undergoes a
conformational rearrangement that results in formation of a pro-
tein interaction surface, the activation function 2 (AF-2) domain,
which binds with the 23FQNLF27 motif near the AR N-terminus.
This intermolecular interaction, known as N/C-terminal inter-
action, is essential for androgen-dependent activation of specific
genes (He et al., 2002). To establish whether N/C-terminal inter-
action of the polyQ AR played a role in aggregation and cell
death, the effects of bicalutamide, a transcriptional antagonist of
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the AR, were tested in a cell model of SBMA and motor neurons
from transgenic AR112Q mice (Orr et al., 2010). Bicalutamide not
only decreased polyQ AR N/C-terminal interactions, but reduced
nuclear inclusion formation in PC12 cells expressing AR112Q,
even in the presence of DHT. Furthermore, AR112Q PC12 cells
and primary neurons were substantially protected from DHT-
induced cell death by the addition of bicalutamide. Mutations in
the 23FQNLF27 motif of AR112Q also reduced DHT-dependent
cell toxicity and polyQ AR aggregation, suggesting that N/C-
terminal interaction must be maintained in order for the polyQ
AR to exhibit its pathogenic gain-of-function properties.
ALTERED PROTEIN INTERACTIONS
The AR NTD contains a transactivation domain that participates
in multiple protein–protein interactions with general transcrip-
tion factors and co-regulatory proteins. Thus changes in the AR
NTD induced by polyglutamine expansion (Davies et al., 2008)
can potentially strengthen or diminish the interaction of the polyQ
AR with these proteins (Figure 2). Overall, the wt AR is known
to interact directly with more than 236 distinct proteins (Got-
tlieb et al., 2012). For instance, the SIRT1 deacetylase binds to the
AR (Fu et al., 2006), and modulates aggregation and polyQ AR
proteotoxicity (Montie et al., 2011). Several proteins differentially
interact with the wt or polyQ AR, implicating different pathways
in SBMA pathogenesis. While cytochrome c oxidase subunit Vb
(COXVb) interacted more strongly with wt AR than polyQ AR in
a hormone-dependent manner, COXVb co-localized with polyQ
AR, but not wt AR aggregates (Beauchemin et al., 2001), which
may contribute to mitochondrial dysfunction in SBMA. In the
presence of DHT, retinoblastoma protein (Rb) weakly associated
with wt AR, but interacted strongly with the polyQ AR, leading
to aberrant E2F1 transcriptional activation (Suzuki et al., 2009).
The p23 protein, an essential component of the multichaperone
Hsp90 complex, was more highly associated with the polyQ AR
than the wt AR, which may be the basis for the preferential degra-
dation of the polyQ AR after 17-AAG treatment (Waza et al., 2005).
AR113Q, but not AR10Q, specifically interacted with PTIP (Pax
Transactivation-domain-interaction Protein), a protein that func-
tions in DNA repair, suggesting the polyQ AR may dampen the
DNA damage response, leading to an accumulation of mutation
and cellular dysfunction in SBMA (Xiao et al., 2012). The full
impact on cellular functions mediated by novel or altered inter-
actions between the polyQ AR and other proteins is still being
explored.
NUCLEAR TRANSLOCATION
The ligand-dependent translocation of AR to the nucleus is
required for the receptor to carry out its classical functions as a
transcription factor. Transgenic mice expressing a polyQ AR with
a deletion within the AR bipartite NLS (ARdNLS112Q) exhib-
ited delayed onset and reduction of motor deficits compared to
AR112Q mice. The nuclear accumulation of ARdNLS112Q in the
spinal motor neurons of the ARdNLS112Q mice was also deferred
relative to the AR112Q mice. Interestingly, in PC12 cells express-
ing a polyQ AR with a constitutive-acting NLS (NLSX3-AR76Q),
although the NLSX3-AR76Q protein localized to the nucleus in
the absence of DHT, neither intranuclear inclusions nor cell death
FIGURE 2 | Examples of polyQ AR loss- and gain-of-function in SBMA.
(A) Transcriptional dysregulation. The polyQ AR may activate expression of
certain genes to a lesser (top) or greater (bottom) extent than the wt AR.
(B) Altered protein interactions. The polyQ AR may fail to associate with
proteins (top) or bind more strongly to proteins (bottom) that normally
interact with the wt AR.
were observed. However, upon DHT treatment of the NLSX3-
AR76Q cells, inclusions consisting of N-terminal AR fragment
formed, and levels of cell death increased.
In a Drosophila model, transgenic flies that expressed the
AR73Q protein with mutations in the NLS (K633A and K634A;
AR73Q KK/AA) were generated (Nedelsky et al., 2010). In addi-
tion, a polyQ AR incapable of binding DHT (S215D and S792D
mutations; AR65Q SS/DD) was fused to a NLS, to produce NLS-
AR65Q SS/DD transgenic flies. Drosophila expressing AR52Q or
AR65Q-NLS developed an SBMA eye phenotype when fed DHT,
however, the AR73Q KK/AA or NLS-AR65Q SS/DD flies showed
no signs of photoreceptor degeneration, even when raised on DHT.
Overall, these results from these two models indicate that the
polyQ AR must be localized within the nucleus, in the presence of
its ligand, to induce SBMA disease features.
AGGREGATES AND NUCLEAR INCLUSIONS
The accumulation of misfolded and aggregated proteins is a patho-
logical hallmark of many neurodegenerative diseases, including
ALS and polyglutamine diseases (Pandey et al., 2007a). How-
ever, immunohistochemical examination of tissues from SBMA
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patients with the 1C2 antibody (a monoclonal antibody that
specifically recognizes expanded polyglutamine tracts) showed
that diffuse nuclear accumulation of the polyQ AR was far more
frequent and extensive than nuclear inclusions, was distributed in a
wide array of CNS nuclei, and present in more visceral organs than
previously identified (Adachi et al., 2005). Cytoplasmic accumula-
tions of the polyQ AR were also detected in neural and non-neural
tissues (Adachi et al., 2005). Although there are conflicting views
on whether polyQ AR aggregates or nuclear inclusions have a detri-
mental or a protective effect (Taylor et al., 2003; Beitel et al., 2005),
these aggregates may be an indicator of the intracellular inabil-
ity to remove misfolded proteins (Li et al., 2008). Furthermore,
the 1C2-reactive neuronal inclusions can be detected using anti-
bodies directed against specific AR N-terminal regions, but not
the DNA- or ligand-binding domains, strongly suggesting that
proteolytic cleavage of the polyQ AR generates truncated frag-
ments that are incorporated into the inclusions (Butler et al.,
1998; Li et al., 1998; Merry et al., 1998; Chevalier-Larsen et al.,
2004). As well, numerous cellular protein have been found to be
sequestered into neuronal intranuclear inclusions including HSPs
(Hsp40, Hsp70, Hsp90), UPS components (ubiquitin, 19S and 20S
proteasome core proteins), and several AR co-activators and tran-
scriptional proteins (CBP, SRC-1) (Rusmini et al., 2011; Schindler
et al., 2012).
The first 50 amino acids of the polyQ AR (e.g., filamen-
tous actin-binding sequences) can directly affect aggregation rate,
the SDS solubility and the subcellular localization of aggregates
(Angeli et al., 2010). Using a FRET assay to measure aggregation
of a polypeptide containing the first 127 amino acids of AR, it was
determined that coexpression of profilin, an actin-binding protein,
inhibited polyQ AR aggregation (Shao et al., 2008). Conversely,
cofilin, an F-actin-severing and -depolymerizing factor, increased
aggregation, suggesting that the actin cytoskeleton activity may
influence polyQ AR aggregation. Disrupting interaction between
AR and the ARA70 coactivator in PC12/AR10Q cells with ASC-
J9 (5-hydroxy-1,7-bis(3,4-dimethoxyphenyl)-1,4,6-heptatrien-3-
one) promoted AR degradation (Yang et al., 2007). ASC-J9 also
reduced aggregate formation and polyQ AR-induced cell death
in PC12 AR112Q cells, and in AR97Q transgenic mice reversed
muscular atrophy, and improved motor impairment and lifes-
pan. Similar effects were seen in neuronal cells and transgenic
mice when genistein, a soy isoflavone, was used to disrupt polyQ
AR-ARA70 interactions (Qiang et al., 2013). Thus, decreasing
aggregate formation by treatment with compounds that disrupt
AR-protein interactions may allow the polyQ AR to be degraded,
with beneficial effects.
FORMATION OF SOLUBLE OLIGOMERS
In several SBMA models, the presence of large intracellular inclu-
sions does not correlate with neuronal toxicity or SBMA phe-
notype (Table 1), suggesting other forms of the polyQ AR may
be pathogenic. For example, expression of N-terminal truncated
polyQ AR fragments in neuronal cells activated c-jun N-terminal
kinase (JNK), leading to phosphorylation of c-Jun, which then
initiated a Bax-dependent apoptotic cascade (Young et al., 2009).
It has also been proposed that soluble polyQ AR NTD fragments
can interact with the full-length polyQ AR and impair its trans-
activation capacity (Schiffer et al., 2008). Although intracellular
polyQ AR aggregates are identified using histopathological meth-
ods, oligomers have been defined as submacromolecular structures
that are soluble after high-speed centrifugation and are com-
prised of ordered polyglutamine aggregates (Li et al., 2007). In
brain extracts from symptomatic male AR112Q mice, the AR112
monomer (∼130 kDa) and an intermediate molecular weight
smear (∼250–450 kDa) suggestive of soluble oligomers of polyQ
AR protein, were identified by Western blotting (Li et al., 2007).
Formic acid treatment has been shown to dissociate SDS-insoluble
protein aggregates stabilized by hydrogen bonds, but does not
cleave isopeptide bonds. Treatment with formic acid dissociated
the polyQ oligomers from SBMA mice and indicated that the
oligomers contained a distinct polyQ AR N-terminal fragment of
∼50 kDa. In the male AR112 mice, the oligomers appeared before
the onset of motor dysfunction, and did not correlate with the
occurrence of nuclear inclusions. However, upon castration, which
reversed polyQ-induced pathology in the male AR112 mice, the
levels of oligomers decreased rapidly, further implicating soluble
polyQ AR oligomers in SBMA pathogenesis.
POST-TRANSLATIONAL MODIFICATIONS
AR function, trafficking, and turnover are dynamically regulated
by a variety of post-translational modifications including phos-
phorylation, acetylation, ubiquitination, sumoylation, and methy-
lation (Figure 1) (Montie et al., 2011; Anbalagan et al., 2012;
Coffey and Robson, 2012). These modifications can occur through
both androgen-independent and androgen-dependent mecha-
nisms. Notably, the polyQ AR was found to be acetylated and
phosphorylated in the absence of ligand, while the wt AR under-
went these post-translational modifications only in the presence
of ligand (Lieberman et al., 2002).
In cells expressing the polyQ AR, phosphorylation of AR112 at
S516 via the p44/42 MAP kinase pathway was required to induce
cell death (LaFevre-Bernt and Ellerby, 2003). It was proposed that
this phosphorylation event enhanced the ability of caspase-3 to
cleave the AR112Q and generate cytotoxic polyQ fragments. Akt
(also known as protein kinase B) phosphorylates the wt AR at
S215 and S792 (Lin et al., 2001). Phosphorylation of AR65Q
at the same Akt consensus sites reduced androgen binding and
transcriptional activation, and decreased ligand-induced protein
stabilization and nuclear translocation (Palazzolo et al., 2007).
Insulin-like growth factor 1 (IGF-1) stimulation increased the
survival rate of the MN-1 cells stably expressing AR65Q through
the phospho-inositol-3-kinase (PI3K) pathway and activation of
Akt. IGF-1/Akt signaling also reduced polyQ AR aggregation and
increased polyQ AR degradation by the UPS in a phosphorylation-
dependent manner (Palazzolo et al., 2009). To study the effects of
IGF-1 in vivo, transgenic AR97Q mice were crossed with mice
overexpressing a rat, non-circulating, muscle-specific isoform of
IGF-1. The AR97Q/IGF-1 mice had reduced polyQ AR aggrega-
tion in muscles and spinal cord, decreased muscle weakness, less
motor neuron loss, improved motor function, and extended life
span compared to AR97Q mice, strongly suggesting that augmen-
tation of IGF-1/Akt signaling could counteract the phenotypic
and pathological abnormalities caused by the polyQ AR. Fur-
ther studies showed systemic treatment of symptomatic AR97Q
mice with recombinant human IGF-1 and IGF-1 binding protein
3 (rhIGF-IGFBP3) resulted in increased Akt activation, reduced
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polyQ AR aggregation and pathology in muscles, improved motor
function and increased survival (Rinaldi et al., 2012). Phosphory-
lation at Akt sites can thus modulate the detrimental effects of the
polyQ AR.
Acetylation of wt AR at three lysine residues (K631, K633, and
K634) within the AR hinge region is regulated by several acetyl-
transferases including p300, p300/CBP-associated factor (P/CAF),
and TIF60 (Tat-interactive protein). Androgen-induced acetyla-
tion of AR can regulate DNA-binding and enhances AR transcrip-
tional activity in a promoter-dependent context (Anbalagan et al.,
2012; Coffey and Robson, 2012). Conversely, deacetylation down-
regulates AR activity. SIRT1, a member of the sirtuin family of
deacetylases, interacts with and deacetylates the wt AR at the con-
served lysine motif, inhibiting DHT-dependent wt AR signaling
and N/C interaction (Fu et al., 2006). PC12 cells inducibly express-
ing AR112Q form polyQ length and DHT-dependent nuclear
inclusions of proteolyzed polyQ AR, and die in response to DHT
(Montie et al., 2011). In the presence of androgens, nuclear-
localized AR112Q was hyperacetylated compared to the AR10Q.
Stable overexpression of SIRT1 in this model reduced the number
of cells with nuclear inclusions and the amount of SDS-insoluble
AR112Q seen on Western analysis. SIRT1 overexpression also
protected PC12 cells expressing AR112Q, and motor neurons
from AR112Q mice, from DHT-dependent death, demonstrating
that abnormal acetylation is associated with aberrant polyQ AR
function in SBMA.
Sumoylation, the process of covalently attaching small
ubiquitin-like modifier (SUMO) to proteins, is mediated by acti-
vating, conjugating and ligating enzymes, and reversed by a family
of SUMO-specific proteases (SENPs) (Anbalagan et al., 2012).
Sumoylation of the wt AR at K388 and K521 in the NTD can inhibit
AR transcriptional activity in a promoter context-dependent man-
ner (Mukherjee et al., 2009). Expansion of the polyglutamine tract
in the AR does not appear to interfere with AR sumoylation.
However, increasing SUMO levels in AR113Q-expressing HeLa
cells decreased the fraction of cells containing ligand-induced AR
aggregates, without affecting total polyQ AR levels. Thus, sumoyla-
tion reduced the formation of polyQ AR aggregates independently
of its effect on AR113Q transcription activity.
TRANSCRIPTIONAL DYSREGULATION
Dysregulation of transcriptional events is considered to be a major
molecular mechanism through which the polyQ AR contributes
to the development of SBMA. The pathogenic polyQ AR accumu-
lates in the cell nucleus in a ligand-dependent manner and may
inhibit transcription by interfering with the function of essential
transcriptional factors and co-activators (Katsuno et al., 2005).
For example, in SBMA cell models, transgenic mice and tissues
from SBMA patients, transcriptional co-activators such as CREB-
binding protein (CBP) can be sequestered into nuclear inclusions
formed by the polyQ AR (McCampbell et al., 2000). AR transcrip-
tional competence has been found to decrease as polyglutamine
tract length increases (Kazemi-Esfarjani et al., 1995; Thomas et al.,
2006b; Palazzolo et al., 2008). Microarray analysis of MN-1 cells
stably expressing 24Q or 65Q AR showed that specific genes that
were up- or down-regulated in an androgen-responsive fashion by
the wt AR failed to be activated by the polyQ AR, indicative of a
partial loss of AR transcriptional activity (Lieberman et al., 2002)
(Figure 2). In NSC34 cells, the polyQ AR was found to act in DHT-
dependent promoter specific context, as ARQ.48 was less effective
than AR.Q22 in inducing transcription from classical AREs, but
acted similarly to AR.Q22 in repressing transcription from a pro-
moter with a non-classical ARE silencer region (Vismara et al.,
2009).
In mouse models of SBMA, decreases in the mRNA levels
of vascular endothelial growth factor (VEGF) (Sopher et al.,
2004), skeletal muscle chloride channel 1 (CLCN1), skeletal muscle
sodium channel α-subunit, neurotrophin-4 (NT-4), glial cell line-
derived neurotrophic factor (GDNF) (Yu et al., 2006a), dynactin
1 (Katsuno et al., 2006), genes related to mitochondrial function
(Ranganathan et al., 2009), and TGF-β receptor type II (TGF-
βRII) (Katsuno et al., 2010a) have been described. Gene expression
analysis by qPCR showed muscles from men with SBMA and
male AR113Q mice, but not spinal cords or spinal motor neu-
rons, contained significantly higher levels of several mRNAs that
are induced in response to endoplasmic reticulum (ER) stress
(Yu et al., 2011). Microarray analysis of spinal cords of AR97Q
mice showed the gene encoding calcitonin gene-related peptide
α (CGRP1) was upregulated, and mediated neuronal damage via
activation of the JNK pathway (Minamiyama et al., 2012). Inter-
estingly, although mutations in the FUS (fused in sarcoma) gene
are associated with ALS, no evidence of altered FUS expression was
found in the spinal cord or motor neurons of AR100 mice (Fratta
et al., 2013).
A global characterization of gene expression in three mice
models that substantially reproduce an SBMA phenotype was
also pursued (Mo et al., 2010). Microarray analyses of the lower
hind limb muscles of AR113Q knock-in, AR97Q transgenic, and
HSA-AR transgenic mice, relative to wt mice, were carried out.
The patterns and levels of transcription of a number of genes
were found to be altered in all models. In the polyQ AR mod-
els, genes functionally associated with metal ion binding, steroid
metabolism, muscle contraction, filamentous actin, endocytosis,
chemical homeostasis, and macrophage activation were found to
be down-regulated, while genes involved in hydrolase activity, pro-
tein binding,and peptidase activity were upregulated. These results
support the hypothesis that altered gene expression due to the pres-
ence of the polyQ AR may underlie the muscle wasting and motor
neuron loss seen in SBMA.
Intriguingly, microRNA (miRNA) expression can also be
altered due to the polyQ AR (Miyazaki et al., 2012). Over 500
miRNAs were analyzed using microarrays, and five miRNAs were
upregulated more than twofold in the spinal cord of AR97Q mice at
an advanced disease stage relative to the AR 24Q mice. At this point,
the mechanisms by which the polyQ AR up-regulates miRNAs and
the consequences are unknown.
ALTERED RNA SPLICING
Alternative splicing allows for the synthesis of different products
from the same gene, increasing the diversity of proteins that can be
generated from a limited number of genes. The role of the wt AR in
RNA processing and splicing is presently unclear, although the AR
has been shown to interact in a ligand-dependent manner with
RNA splicing factors PTD-associated (PSF) and p54nrb (Dong
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et al., 2007). Hormone- and glutamine length-dependent missplic-
ing of the chloride channel 1 (Clcn1) gene and increased expression
of the CUGBP1 RNA-binding protein has been demonstrated in
SBMA AR113Q knock-in mice (Yu et al., 2009). In AR21Q mice,
however, skeletal muscle denervation also induced CUGBP1, but
did not alter Clcn1 RNA splicing, suggesting that a combination
of denervation- and polyQ AR-mediated mechanisms is required
to alter RNA processing in SBMA model mice (Yu et al., 2009). In
in vitro studies, the human cardiac troponin T (cTNT) minigene
construct was transfected into HeLa cells as a reporter to determine
the effect of the wt or polyQ AR on RNA splicing. Expression of
the AR24Q in the presence of ligand or the AR112Q in the absence
or presence of ligand resulted in increased cTNT exon 5 inclusion.
Transcription and RNA processing of the mouse mammary tumor
virus (MMTV) driven-calcitonin/calcitonin gene-related peptide
(CT/CGRP) minigene is affected by steroid hormone receptors
(Auboeuf et al., 2007). Although activation of the AR24Q by ligand
slightly increased the CT/CGRP transcript ratios, ligand activation
of AR112Q caused a significantly greater increase in this ratio (Yu
et al., 2009). Thus, the polyQ AR can influence androgen-regulated
RNA processing and splicing events, although the precise effects
of altered RNA metabolism on cellular function in SBMA patients
remain to be determined.
UBIQUITIN PROTEASOME SYSTEM IMPAIRMENT
Protein homeostasis is regulated in the cell by two principal
degradative mechanisms: the ubiquitin proteasome system (UPS),
which processes short lived and misfolded proteins for degradation
(Ciechanover and Brundin, 2003), and autophagy (Rubinsztein,
2006). Ubiquitination is the enzymatic process that occurs when
a ubiquitin moiety is attached to a protein via a highly structured
enzymatic cascade that involve an activating enzyme (E1), a con-
jugating enzyme (E2), and a ubiquitin ligase enzyme (E3) that is
substrate specific (Ciechanover and Brundin, 2003). The wt AR-
protein undergoes post-translational modifications that modulate
its activity, including ubiquitination (Coffey and Robson, 2012;
Gioeli and Paschal, 2012) (Figure 1). Mass spectrometry analy-
ses have found two ubiquitination sites in the AR protein, K846,
and K848 (Xu et al., 2009). Ubiquitin ligases identified for the AR
include MDM2 (Lin et al., 2002), C-terminus of heat-shock cog-
nate protein 70 (Hsc70)-interacting protein (CHIP) (Chymkow-
itch et al., 2011) and RNF6 (Xu et al., 2009). MDM2 and CHIP
target the AR for degradation by polyubiquitinating it, while ubiq-
uitination by RNF6 promotes AR-dependent transcription (Xu
et al., 2009). Additional UPS proteins that interact directly with
and coactivate the wt AR are an E2 (UbcH7), several E3s (ARA54,
E6-AP,hPIRH2/ARNIP),a deubiquitinating enzyme (USP10),and
a proteasomal subunit (Rpt5/PSMC3) (Gottlieb et al., 2012). AR
function and the UPS may therefore overlap in a number of areas,
beyond proteasome-mediated degradation.
One of the characteristic features of the neurodegenerative
polyglutamine diseases is the presence of inclusion bodies that
colocalize with components of the UPS and the molecular chap-
erone pathway (Adachi et al., 2001), indicating that the mutant
proteins are targeted for degradation (Stenoien et al., 1999). Poten-
tially, sequestration of UPS components or inhibition of the UPS
by polyQ proteins could alter protein repair and degradation
pathways and thus have been implicated in the pathogenesis of
polyglutamine diseases (Bailey et al., 2002; Rusmini et al., 2010).
Degradation of an unstable green fluorescent protein reporter
(GFPu) decreased when HEK293-GFPu cells expressing the polyQ
AR were treated with androgens, suggesting that proteasome activ-
ity was inhibited by the polyQ AR (Mandrusiak et al., 2003).
Androgen-dependent polyQ AR (121Q) UPS impairment was
also observed in SBMA flies expressing a reporter for protea-
some function (Pandey et al., 2007b). In contrast, in an NSC34
cell model of SBMA, unliganded soluble polyQ impaired the cyto-
plasmic UPS, and, although testosterone binding induced polyQ
AR aggregation, nuclear UPS activity was unaffected (Rusmini
et al., 2007). Proteasomal proteolytic activity was also preserved in
AR97Q mice, even when they developed a severe phenotype (Tokui
et al., 2009). At this point, the complex processes that may lead to
proteasomal inhibition and the extent to which UPS dysfunction
contribute to SBMA require further investigation.
AUTOPHAGY
Macroautophagy, often simply called autophagy, is the process by
which misfolded or damaged proteins are targeted for degradation
through the lysosomal system (Rubinsztein, 2006). The role of
autophagy has been assessed in several SBMA models. Transgenic
Drosophila expressing full-length hAR with 52Q or 121Q displayed
ligand-dependent, polyQ AR-dependent degeneration of specific
neurons, resulting in a rough eye phenotype (Pandey et al., 2007b).
This phenotype was associated with UPS impairment and induc-
tion of morphological features of autophagy. Inducing autophagy
in this fly model, through overexpression of histone deacetylase
6 (HDAC6), accelerated the turnover of the polyQ AR and low-
ered steady-state levels of monomeric and aggregated polyQ AR.
Treatment with the TOR inhibitor rapamycin also suppressed
degeneration, suggesting a compensatory relationship between
autophagy and the UPS. Activation of autophagy in motor neu-
rons from AR112Q mice also prevented DHT-dependent death
induced by nuclear-localized polyQ AR, although, unlike in the fly
model, a reduction in the levels of monomeric polyQ AR was not
seen (Montie et al., 2009). In NSC34 cells, 17-AAG (17-allylamino,
17-demethoxygeldamycin) treatment promoted the solubility and
degradation of the misfolded AR.Q46 through the autophagic
pathway, without affecting the UPS (Rusmini et al., 2011).
The unfolded protein response (UPR), an ER protein qual-
ity control pathway, was found to be induced in skeletal muscle
from SBMA patients and male AR113Q knock-in mice (Yu et al.,
2011). Unexpectedly, genetic disruption of the UPR in the AR113Q
mice worsened skeletal muscle atrophy, even though autophagy
was activated. Conversely, impairing autophagy decreased muscle
wasting and prolonged survival of the SBMA mice. The contrasting
results seen with the pharmacological and genetic manipulation
of autophagy in these SBMA models highlights the complexity of
the relationship between the UPR, autophagy, and the UPS, as well
as the ability of these systems to clear the polyQ AR from different
tissues and subcellular compartments.
HEAT-SHOCK PROTEINS
Heat-shock proteins are molecular chaperones that facilitate
the refolding, assembly and intercellular transport of proteins.
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The wt AR is normally stabilized by the chaperone activity of
Hsp90/Hsp70 complex, which maintains the AR in a conformation
that permits androgen binding (Wang et al., 2010). Overexpres-
sion of Hsp70, and Hsp40, inhibited accumulation of the polyQ
AR protein and suppress cell death in several cells models (dis-
cussed in Beitel et al., 2005; Katsuno et al., 2005). Oral treatment
of transgenic AR97Q mice with geranylgeranylacetone (GGA),
which induced Hsp70, Hsp90, and Hsp105 expression in the cen-
tral nervous system and skeletal muscle, inhibited the nuclear
accumulation of the polyQ AR, and ameliorated the neuromus-
cular phenotype (Katsuno et al., 2005). Treatment of AR100 mice
with arimoclomol, a co-inducer of the heat-shock stress response,
upregulated Hsp70 in spinal cord and hindlimb muscle, improved
neuromuscular function and motor neuron survival, and delayed
disease progression (Malik et al., 2013). Overexpression of Hsp70
interacting protein (Hip), a co-chaperone that stabilizes Hsp70,
in AR112Q-expressing HeLa cells enhanced clearance of soluble
and ligand-induced insoluble polyQ AR proteins through the UPS
(Wang et al., 2013). Similarly, a small molecule (YM-1) that con-
verted Hsp70 to its tight-affinity conformation, increased Hsp70-
dependent degradation of hormone-induced AR113Q oligomers
in tetracycline-inducible PC12 cells, and partially rescued the
DHT-dependent rough eye phenotype in UAS-AR52 flies (Wang
et al., 2013). In contrast, inhibition of Hsp70 by methylene blue
impaired degradation and enhanced aggregation of full-length
AR112Q in HeLa cells (Wang et al., 2010).
The Hsp90/Hsp70-based chaperone machinery is part of the
cellular defense against unfolded proteins (Morishima et al., 2008).
When Hsp90 heterocomplex assembly is blocked by specific Hsp90
inhibitors like geldanamycin, the client proteins undergo rapid
degradation through UPS, assisted by E3 ligases such as CHIP.
Indeed, CHIP functions as a negative regulator of wt AR transcrip-
tional activity by promoting AR degradation (He et al., 2004). In
SH-SY5Y cells, increasing levels of CHIP effectively ubiquitinated
and degraded the monomeric polyQ AR more efficiently than the
wt AR, suggesting that the polyQ AR is more sensitive to CHIP
than the wt AR (Adachi et al., 2007). Overexpression of CHIP in
AR97Q transgenic mice also inhibited neuronal nuclear accumu-
lation of polyQ AR and ameliorated motor symptoms (Adachi
et al., 2007). However, the AR112Q protein was degraded at the
same rate in CHIP-deficient and CHIP-positive mouse embryonic
fibroblasts after treatment with geldanamycin, strongly suggesting
that redundant E3 ligases promote polyQ AR degradation through
the UPS (Morishima et al., 2008). Further analysis indicated that
Hsp90 inhibition by geldanamycin in heat-shock transcription
factor (Hsf1)-null mouse embryonic fibroblasts did not increase
Hsp70 and Hsp40 levels, but still prevented AR112Q aggrega-
tion, possibly by inhibiting Hsp90-mediated retrograde trafficking
(Thomas et al., 2006a).
A less toxic derivative of geldanamycin, 17-AAG, also shifts
the Hsp90 complex toward its proteasome-targeting form, leading
to enhanced UPS degradation of Hsp90 client proteins. 17-AAG
treatment preferentially degraded the polyQ AR relative to the
wt AR in both SH-SY5Y cells, and spinal cord and muscle of
transgenic AR97Q mice, thus reducing monomeric and aggre-
gated polyQ AR levels, and decreasing motor impairment in
AR97Q mice (Waza et al., 2005). Similar effects were seen in cells
and AR97Q mice treated with 17-(dimethylaminoetylamino)-17-
demthoxygeldanamycin (17-DMAG), a more potent derivative
of 17-AAG (Tokui et al., 2009). Manipulation of Hsp70 and
Hsp90 activity can therefore influence poly Q AR stability and
degradation.
LOSS OF NEUROTROPHIC SUPPORT
Initially, it was postulated that the polyQ AR gained functions
that were harmful to motor neurons, resulting in neuronal loss
and denervation-induced muscular atrophy in SBMA. How-
ever, another mechanism contributing to neuronal degeneration
observed might be the loss of AR-dependent functions that sup-
port neuronal cell survival. Although each polyglutamine disease
appears to specifically affect different subsets of neurons, SBMA
is the only one to cause selective degeneration of motor neurons
(Orr and Zoghbi, 2007). As described above, AR100Q mice devel-
oped a more severe motor neuron phenotype in the absence of the
endogenous wt AR (Thomas et al., 2006b). This implies that the
wt AR may play a role in supporting motor neurons and that the
polyQ AR is dysfunctional with respect to protecting the neurons
from degeneration (Cary and La Spada, 2008). Neurotrophins,
including brain-derived neurotrophic factor (BDNF), ciliary neu-
rotrophic factor (CNTF), and GDNF, are small peptide hormones
that promote motor neuronal growth and survival (Cary and La
Spada, 2008). VEGF and IGF-1 also display motor neuron-specific
trophism. Muscles from SBMA patients showed decreased expres-
sion of GDNF (Yamamoto et al., 1999). Decreased expression of
GDNF, IGF-1, and NT-4 were seen in the AR113Q knock-in mice
(Yu et al., 2006a), while lower VEGF levels were found in the AR
100Q YAC mouse model (Sopher et al., 2004). Signaling through
the AR itself could also protect specific motor neurons by inducing
transcription of genes involved in promoting motor neuron sur-
vival (Cary and La Spada, 2008). It is also thought that the BDNF
produced by muscle can be transported in a retrograde fashion
and thus act as a trophic factor to support motor neurons (Fargo
et al., 2008).
The lower motor neurons in the spinal cord and brainstem
express high levels of AR, and growth of their elaborate dendritic
arbors and extremely long axons is developmentally regulated by
androgens (Fargo et al., 2008). In NSC34 cells stably transfected
with mouse wt AR, androgens enhanced motor neuron differenti-
ation and neurite outgrowth, likely through upregulation of neu-
ritin (Marron et al., 2005). Motor neurons expressing the polyQ
AR, however, developed neurites that were typically short and dys-
trophic, with abnormal branching patterns (Poletti, 1999). These
results suggest that the polyQ AR may prevent the normal pattern
of connectivity of motor neurons by interfering with control of
their neurite outgrowth. The loss of connectivity with the target
musculature could eventually result in death of the motor neurons
(Fargo et al., 2008). As well, the polyQ AR may fail to upregulate
neuritin, which otherwise might mitigate the detrimental effects
of polyQ AR aggregates and allow the motor neurons to maintain
or recover normal axonal functionality (Fargo et al., 2008).
MYOGENIC MECHANISMS
The supposition that SBMA is of neurogenic origin (i.e., origi-
nates from neuronal degeneration) has been broadened to include
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the possibility that this disorder may also have a myogenic con-
tribution. The AR113Q knock-in mice developed early androgen-
dependent neuromuscular weakness, and myopathic and neuro-
genic skeletal muscle pathology was observed before neuronal
intranuclear inclusions were seen in the spinal cord (Yu et al.,
2006a). Unexpectedly, transgenic mice overexpressing the wt AR in
skeletal muscle, but not spinal motor neurons (HSA-AR; Table 1),
developed an androgen-dependent SBMA-like phenotype (Monks
et al., 2007). Although prominent nuclear staining for AR in mus-
cle fibers was observed, there was no evidence for AR-positive
aggregates. The male HSA-AR mice exhibited a phenotype sim-
ilar to other SBMA mouse models, with kyphosis, reduced body
weight, weakness, and motor dysfunction. The skeletal muscles
of the HSA-AR mice show pathological abnormalities consistent
with an SBMA phenotype (myopathy), and signs of motor axon
loss, but no loss in the number of motor neuron cell bodies. Myo-
genin and acetylcholine receptor (AChR) α-subunit mRNA levels
were upregulated in HSA-AR muscles, consistent with neurogenic
atrophy, while VEGF, a candidate trophic factor for motor neu-
rons, was down-regulated. These results raised the prospect that
diseases such as SBMA that have been regarded as “motor neuron
diseases” result from processes that originate in muscle, and even-
tually cause pathology in motor neurons, possibly due to loss of
muscle-derived neurotrophic factors (Monks et al., 2007, 2008; Yu
et al., 2011).
HSA-AR female transgenic mice were asymptomatic, but
rapidly lost motor function when exposed to male levels of testos-
terone (Johansen et al., 2009). Neither motor neuron nor muscle
fiber losses were seen, however, motor deficits were associated with
androgen-dependent changes in muscle gene expression. Further-
more, the HSA-AR mice were crossed with tfm mice to generate
tfm/HSA-AR mice with functional AR only in skeletal muscles
(Johansen et al., 2011). The tfm/HSA-AR males had tfm-like
external genitalia, undescended atrophic testis, low levels of cir-
culating testosterone, but no signs of an SBMA phenotype. Upon
testosterone treatment, however, these mice developed a profound
neuromuscular phenotype, even though they lacked AR expression
in motor neurons. When testosterone treatment was stopped after
9 days, the tfm/HSA-AR males rapidly regained motor function
and body weight. Overall, these experiments suggest that cellular
dysfunction, rather than loss, underlie the motor deficits triggered
by testosterone in the HSA-AR mice.
Investigating the AR113Q mice has also shed light on the role of
the polyQ AR in the neuromuscular weakness seen in SBMA (Yu
et al., 2011). The male AR113Q mice had less forelimb strength
compared to their wt littermates, and morphological changes
in skeletal muscle were indicative of both neurogenic and myo-
pathic effects. As in the HSA-AR mice, the skeletal muscles of the
AR113Q expressed higher levels of myogenin and AChR α-subunit
compared with wt muscle, reflective of denervation. Intranuclear
inclusions were detected in muscles of AR113Q males before neu-
ronal intranuclear inclusions developed in their spinal cord. These
results suggest that SBMA is initiated by myopathic effects in skele-
tal muscle, combined with either functional denervation or distal
axonopathy that is reflective of motor neuron dysfunction, and
that motor neuron loss is a late manifestation of SBMA (Yu et al.,
2011).
NON-GENOMIC AR SIGNALING
Androgens can stimulate cell growth and survival through both
genomic and non-genomic pathways (Foradori et al., 2008). In the
classical view, most androgen action is mediated by an intracellular
AR acting at the genomic level as a transcription factor. However,
the wt AR is also known to interact with second messenger signal-
ing cascades, such as the mitogen-activated protein kinase (MAPK)
pathway (Cary and La Spada, 2008). Investigations into signal-
ing pathways modulated by membrane-associated ARs were per-
formed by inducing expression of AR20Q and AR51Q in NSC34
cells (Schindler et al., 2012). The NSC34/AR51Q cells formed
neither insoluble cytoplasmic aggregates nor nuclear inclusions,
however, both neurite outgrowth and cell viability were decreased
compared to AR20Q-expressing cells. Both the wt AR and polyQ
AR localized to the plasma membrane and migrated to lipid rafts
upon testosterone treatment, but only the AR20Q activated c-jun,
through the JNK pathway. Activated c-jun is involved in neurite
outgrowth and cell proliferation, thus these results suggest that the
impairment of non-genomic AR signaling may be involved in the
development of SBMA.
In addition, an association between polyQ AR-mediated motor
neuron damage and disruption of transforming growth factor-β
(TGF-β) signaling due to transcriptional dysregulation of TGF-
β receptor II (TβRII) has been described. The effects of TGF-β
are mediated by transmembrane receptor serine/threonine kinase
complex consisting of TβRI and TβRII. TGF-β binding to the
complex results in phosphorylation of Smad 2 and 3 (pSmad2/3),
which then translocates to the nucleus to regulate gene transcrip-
tion. Nuclear translocation of pSmad2/3 was suppressed in the
spinal cord motor neurons of AR97Q transgenic mice and SBMA
patients (Katsuno et al., 2010a). Spinal motor neuron staining and
immunoblotting also showed decreased levels of TβRII, but not
TβRI, in the SBMA mice and patients. In transfected cells, two
factors that regulate TβRII transcription, P/CAF and NF-Y, co-
localized with truncated AR97Q in inclusion bodies, potentially
causing TβRII down-regulation. As the TGF-β-Smad2/3 signaling
pathway has been shown to have potent neuroprotective effects,
these results suggest that polyQ-AR-mediated inhibition of TGF-β
signaling would result in less effective neuroprotection.
MITOCHONDRIAL DYSFUNCTION
The AR is likely to influence mitochondrial function by regulating
transcription of either mitochondrial proteins (encoded by either
nuclear or mitochondrial DNA) or transcription factors activating
expression of these mitochondrial proteins, or by interacting with
proteins that affect mitochondrial function (Gavrilova-Jordan and
Price, 2007). Direct AR-mitochondrial interactions are also possi-
ble. The wt AR has been localized to mitochondria in human sperm
and LNCaP cells (Solakidi et al., 2005), and both the wt AR and,
to a greater extent, the polyQ AR associated with mitochondria in
cultured MN-1 cells (Ranganathan et al., 2009). The presence of
the polyQ AR can alter mitochondrial distribution; cytoplasmic
ARQ48 aggregates in transfected HeLa cells sequestered mito-
chondria, HSPs, proteasome components and steroid receptor
coactivator 1 (SRC-1) (Stenoien et al., 1999), and mitochondria
were found in polyQ AR aggregates in the NSC34 motor neuron
cell line (Piccioni et al., 2002). Both the wt and polyQ AR interacted
Frontiers in Neurology | Neurodegeneration May 2013 | Volume 4 | Article 53 | 10
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Beitel et al. Polyglutamine-expanded AR dysfunction in SBMA
with COXVb, a nuclear-encoded mitochondrial enzyme involved
in oxidative phosphorylation using a mammalian two-hybrid sys-
tem (Beauchemin et al., 2001). As well, COXVb co-localized to
aggregates formed by the polyQ AR in androgen-treated cells, sup-
porting the proposal that sequestration of mitochondrial proteins
may lead to mitochondrial dysfunction in SBMA (Beauchemin
et al., 2001).
Proliferator-activated receptor gamma coactivator 1 (PCG-1)
is known to regulate mitochondrial biogenesis and function. In
ligand-treated AR65Q MN-1 cells, PGC-1β mRNA levels were
decreased relative to cells expressing the wt AR (Ranganathan
et al., 2009). In addition, mitochondrial transcription factor A,
a nuclear-encoded gene controlled by PGC-1β, the antioxidant
genes superoxide dismutase 1 (SOD1), SOD2, and catalase, and the
mitochondrial protein NADH dehydrogenase 1 gene were down-
regulated. PGC-1β and SOD2 mRNA levels were also signifi-
cantly reduced in male AR113Q knock-in mice. Ligand-dependent
increases in mitochondrial membrane depolarization, elevated
reactive oxygen species (ROS) levels, activation of the mitochon-
drial caspase pathway, and increased cell death were observed in
cells expressing the polyQ AR (Ranganathan et al., 2009). Thus
the polyQ AR likely contributes to mitochondrial dysfunction in
SBMA directly though abnormal associations with mitochondria
or mitochondrial proteins,or indirectly through ligand-dependent
alterations in mitochondrial gene expression, turnover, and res-
piratory function (Beauchemin et al., 2001; Ranganathan et al.,
2009). In addition, it has been proposed that mitochondrial DNA
damage may be involved in pathogenesis of SBMA or serve as
a useful biomarker to monitor disease progression (Su et al.,
2010).
IMPAIRED AXONAL TRANSPORT
Axonal transport moves proteins and organelles between the neu-
ronal cell body and the axon tip (and vice versa), and is essential for
the growth and survival of neurons. Abnormalities in axonal trans-
port have been implicated in neurodegenerative diseases (Morfini
et al., 2009; Sau et al., 2011; Ikenaka et al., 2012). Early studies in
in vitro and cell models suggested that the polyQ AR could hinder
axonal transport (Piccioni et al., 2002; Szebenyi et al., 2003). It was
shown in SH-SY5Y cells and squid axoplasm that the polyQ AR
inhibited fast axonal transport through a pathway that involved
JNK activation, phosphorylation of kinesin-1 heavy chain sub-
units by JNK, and inhibition of kinesin-1 function (Morfini et al.,
2006). Transgenic AR97Q mice were found to have impaired retro-
grade axonal transport, even before the onset of muscle weakness,
with accumulation of neurofilaments and synaptophysin in the
distal motor axon (Katsuno et al., 2006). In addition, expression
levels of dynatin 1, an axon motor for retrograde transport, were
reduced in these mice.
In another study, deficits in retrograde labeling of spinal motor
neurons were seen in both the AR113Q knock-in and HSA-AR
myogenic mouse models of SBMA (Kemp et al., 2011). Live imag-
ing of endosomal trafficking in sciatic nerve axons also showed
disease-induced defects in the flux and run length of endosomes
movement toward the cell body. However, when axonal trans-
port rates were analyzed in cultured primary motor neurons or
in sciatic nerves of AR100 mice, no significant axonal transport
deficits were observed, implying there was no correlation between
impairment of axonal transport and SBMA pathogenesis (Malik
et al., 2011). Further investigation into the discrepancies between
different models with respect to polyQ AR-mediated effects on
axonal transport is warranted.
INSIGHTS FROM DROSOPHILAMODELS
The use of genetic models such as Drosophila melanogaster has
greatly facilitated the study of the underlying molecular mech-
anisms of SBMA. The development of “humanized” AR trans-
genic Drosophila lines has allowed for the ectopic/tissue-specific
expression of the polyQ AR, leading to observable, potentially
disease-related phenotypes. Specifically, the wt and polyQ AR
genes are cloned into UAS expression constructs. Crosses to tissue-
specific GAL4 transgenic fly lines drives the expression of AR in
those selected tissues. Although the phenotypes described using
such genetic systems are not directly linked to the clinical man-
ifestations of SBMA, the observed phenomena are polyQ tract
length-dependent and DHT sensitive. A number of studies have
confirmed the working hypothesis of androgen-dependent cel-
lular toxicity of the polyQ AR and have noted the presence of
protein aggregates in photoreceptor neurons (Chan et al., 2002;
Takeyama et al., 2002; Funderburk et al., 2009; Palazzolo et al.,
2010). Interestingly, DHT-dependent reductions in locomotion in
larvae expressing the polyQ AR have been described (Funderburk
et al., 2009; Nedelsky et al., 2010; Jochum et al., 2012). The role of
autophagy and the UPS in a Drosophila model of SBMA have also
been investigated (Pandey et al., 2007a,b). However, these stud-
ies did not address the molecular mechanisms contributing to the
observable phenotype or effects on other polyQ AR functions,
specifically gene transactivation.
This Drosophila genetic system, however, allows for a high-
throughput screen of large number of gene sets, and was utilized
to screen for genetic interactors that either suppressed or enhanced
the polyQ AR/androgen-dependent phenotype (Murata et al.,
2008; Suzuki et al., 2009; Nedelsky et al., 2010). Murata et al.
(2008) used mutant enhancer trap lines to screen ∼2,000 genes
that when co-driven with the polyQ AR would modulate a rough
eye phenotype. An RNA-binding protein, hoip, was identified that
enhanced the polyQ AR-induced eye phenotype (Murata et al.,
2008). The homologous gene in yeast has been reported to be
involved in rRNA processing (Reichow et al., 2007). By further dis-
secting the hoip protein complex, two more genetic modulators of
the polyQ AR phenotype,nop5 and nop56 were found. As nop5 and
nop56 are part of the small nucleolar ribonucleoprotein complex,
these results suggest translational regulation may play a role in
the neurodegeneration observed in SBMA. Retinoblastoma family
protein (Rbf), the Drosophila homolog of human retinoblastoma
protein (Rb), was found to be a neuroprotective factor (Suzuki
et al., 2009). Rb is known to function through repressing transcrip-
tion of genes regulated by the E2F proteins. The androgen-bound
polyQ AR, but not the wt AR, appeared to impair transrepressive
function of Rb, resulting in aberrant stimulation of E2F-mediated
transactivation.
Specific RNAi lines for candidate genes selected from known
AR coregulators described in the AR mutations database
[http://androgendb.mcgill.ca/; (Gottlieb et al., 2012)] were crossed
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Table 2 | PolyQ AR loss- and gain-of-function mechanisms in SBMA.
Mechanism contributing to SBMA PolyQ AR versus wt AR
Loss-of-
function
Gain-of-
function
Alterations in AR structure X
Altered protein interactions X X
Aggregation X
Formation of soluble oligomers X
Change in post-translational modifications X X
Transcriptional dysregulation X X
Altered RNA splicing ? ?
Ubiquitin proteasome system impairment X
Induction of autophagy X
Loss of neurotrophic support X
Myogenic contributions X X
Non-genomic AR signaling X X
Mitochondrial dysfunction X X
Impaired axonal transport X
with AR52Q flies to screen for modifiers of the fly SBMA pheno-
type. Using this approach, 19 genetic interactors were identified
(Nedelsky et al., 2010). Furthermore, microarray analysis was per-
formed on these SBMA flies to identify putative target genes or
androgen-regulated genes to account for the observed rough eye
phenotype. While a number of differentially expressed genes were
observed, neither corresponding AREs nor presumed ecdysone
response elements (the sole Drosophila steroid hormone receptor)
could be identified. Although an interaction of the polyQ AR with
a number of genes was proposed, there are a number of post-
transcriptional and translation regulatory mechanisms that can
alter gene expression profiles. Nevertheless, the approaches taken
to carry out high-throughput screens in Drosophila are resulting
in novel observations of polyQ AR functions that may contribute
to SBMA.
THERAPY FOR SBMA
Given that SBMA is a ligand-dependent polyglutamine disease,
clinical trials to reduce testosterone or DHT levels in men have
been attempted, but showed only limited improvements in cer-
tain disease features (Ranganathan and Fischbeck, 2010; Banno
et al., 2012). Nonetheless, investigations into the mechanisms
underlying the pathogenesis of SBMA have provided indications
for other potential therapies. These include: (1) reducing poly
Q AR levels by increasing degradation through Hsp-mediated,
UPS or autophagic pathways; (2) decreasing formation of aggre-
gates and/or soluble oligomers, or altering their structure (Jochum
et al., 2012); (3) normalizing transcriptional dysfunction; (4)
altering abnormal polyQ AR post-translational modifications; (5)
decreasing polyQ AR mRNA expression using siRNA or miRNAs
(Miyazaki et al., 2012); (6) regulating polyQ AR N/C interactions
and nuclear localization; (7) modulating AR-coactivator interac-
tions; (8) using antioxidants to reduce ROS levels; (9) inducing
IGF-1/Akt signaling; and (10) treatment with serotonin recep-
tor agonists (Minamiyama et al., 2012). Due to the variety of
molecular mechanisms involved in the development of SBMA,
a combination of therapies may be needed to reduce symptoms
and slow disease progression in men. More details on therapeu-
tic approaches to SBMA may be found in several comprehensive
reviews (Ranganathan and Fischbeck, 2010; Banno et al., 2012;
Fischbeck, 2012; Katsuno et al., 2012; Tanaka et al., 2012; Rocchi
and Pennuto, 2013).
CONCLUSION
It is known that androgens can be neurotrophic and are important
in muscle development. In retrospect, it is perhaps not surpris-
ing that there are both neurodegenerative and neuromuscular
components in SBMA, which is caused by polyglutamine tract
expansion in the receptor that mediates the actions of androgens.
The increase in the length of the polyglutamine tract in the AR
is somewhat analogous to the insertion of a new domain through
alternative splicing, which generates a novel protein. The polyQ
AR retains many of the function of the wt AR, however, it fails to
perform as well as the wt AR in certain roles, and gains novel, often
deleterious, properties (Figure 2; Table 2). Consequently, polyQ
AR-mediated loss- and gain-of-function mechanisms can disturb
cellular homeostasis, leading to neuronal and muscular dysfunc-
tion. Multiple complex and overlapping pathogenic processes have
been shown to contribute to the initiation and development of
SBMA. The relative contribution of each mechanistic pathway,
and thus the potential for therapeutic intervention, will be the
subject for future investigations in this field.
ACKNOWLEDGMENTS
Lenore K. Beitel received support from the Fonds de recherche du
Québec – Nature et technologies (FRQNT).
REFERENCES
Adachi, H., Katsuno, M., Minamiyama,
M., Waza, M., Sang, C., Nak-
agomi, Y., et al. (2005). Widespread
nuclear and cytoplasmic accumu-
lation of mutant androgen recep-
tor in SBMA patients. Brain 128,
659–670.
Adachi, H., Kume, A., Li, M., Nak-
agomi, Y., Niwa, H., Do, J., et al.
(2001). Transgenic mice with an
expanded CAG repeat controlled
by the human AR promoter show
polyglutamine nuclear inclusions
and neuronal dysfunction without
neuronal cell death. Hum. Mol.
Genet. 10, 1039–1048.
Adachi, H., Waza, M., Tokui, K., Kat-
suno, M., Minamiyama, M., Tanaka,
F., et al. (2007). CHIP overexpression
reduces mutant androgen receptor
protein and ameliorates phenotypes
of the spinal and bulbar muscular
atrophy transgenic mouse model. J.
Neurosci. 27, 5115–5126.
Albertelli, M. A., Scheller, A., Brogley,
M., and Robins, D. M. (2006).
Replacing the mouse andro-
gen receptor with human alleles
demonstrates glutamine tract
length-dependent effects on phys-
iology and tumorigenesis in mice.
Mol. Endocrinol. 20, 1248–1260.
Anbalagan, M., Huderson, B., Mur-
phy, L., and Rowan, B. G. (2012).
Post-translational modifications of
nuclear receptors and human dis-
ease. Nucl. Recept. Signal 10, e001.
Angeli, S., Shao, J., and Diamond,
M. I. (2010). F-actin binding
regions on the androgen recep-
tor and huntingtin increase aggre-
gation and alter aggregate char-
acteristics. PLoS ONE 5:e9053.
doi:10.1371/journal.pone.0009053
Auboeuf, D., Batsche, E., Dutertre, M.,
Muchardt, C., and O’Malley, B. W.
(2007). Coregulators: transducing
signal from transcription to alter-
native splicing. Trends Endocrinol.
Metab. 18, 122–129.
Bailey, C. K., Andriola, I. F., Kampinga,
H. H., and Merry, D. E. (2002).
Molecular chaperones enhance
the degradation of expanded
polyglutamine repeat androgen
receptor in a cellular model
of spinal and bulbar muscular
atrophy. Hum. Mol. Genet. 11,
515–523.
Frontiers in Neurology | Neurodegeneration May 2013 | Volume 4 | Article 53 | 12
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Beitel et al. Polyglutamine-expanded AR dysfunction in SBMA
Banno, H., Katsuno, M., Suzuki, K.,
Tanaka, F., and Sobue, G. (2012).
Pathogenesis and molecular targeted
therapy of spinal and bulbar muscu-
lar atrophy (SBMA). Cell Tissue Res.
349, 313–320.
Beauchemin, A. M., Gottlieb, B., Beitel,
L. K., Elhaji, Y. A., Pinsky, L., and
Trifiro, M. A. (2001). Cytochrome
c oxidase subunit Vb interacts with
human androgen receptor: a poten-
tial mechanism for neurotoxicity
in spinobulbar muscular atrophy.
Brain Res. Bull. 56, 285–297.
Beitel, L. K., Scanlon, T., Gottlieb,
B., and Trifiro, M. A. (2005).
Progress in spinobulbar muscular
atrophy research: insights into neu-
ronal dysfunction caused by the
polyglutamine-expanded androgen
receptor. Neurotox. Res. 7, 219–230.
Brinkmann, A. O. (2001). Molecular
basis of androgen insensitivity. Mol.
Cell. Endocrinol. 179, 105–109.
Brinkmann, A. O. (2011). Molecular
mechanisms of androgen action – a
historical perspective. Methods Mol.
Biol. 776, 3–24.
Brooks, B. P., Paulson, H. L., Merry, D.
E., Salazar-Grueso, E. F., Brinkmann,
A. O., Wilson, E. M., et al. (1997).
Characterization of an expanded
glutamine repeat androgen receptor
in a neuronal cell culture system.
Neurobiol. Dis. 3, 313–323.
Bruson, A., Sambataro, F., Querin, G.,
D’Ascenzo, C., Palmieri, A., Agos-
tini, J., et al. (2012). CAG repeat
length in androgen receptor gene
is not associated with amyotrophic
lateral sclerosis. Eur. J. Neurol. 19,
1373–1375.
Butler, R., Leigh, P. N., McPhaul, M.
J., and Gallo, J. M. (1998). Trun-
cated forms of the androgen recep-
tor are associated with polygluta-
mine expansion in X-linked spinal
and bulbar muscular atrophy. Hum.
Mol. Genet. 7, 121–127.
Cary, G. A., and La Spada, A. R.
(2008). Androgen receptor function
in motor neuron survival and degen-
eration. Phys. Med. Rehabil. Clin. N.
Am. 19, 479–494.
Cashman, N. R., Durham, H. D., Blusz-
tajn, J. K., Oda, K., Tabira, T., Shaw,
I. T., et al. (1992). Neuroblastoma x
spinal cord (NSC) hybrid cell lines
resemble developing motor neurons.
Dev. Dyn. 194, 209–221.
Centenera, M. M., Harris, J. M., Tilley,
W. D., and Butler, L. M. (2008).
The contribution of different andro-
gen receptor domains to receptor
dimerization and signaling. Mol.
Endocrinol. 22, 2373–2382.
Chahin, N., Klein, C., Mandrekar, J., and
Sorenson, E. (2008). Natural history
of spinal-bulbar muscular atrophy.
Neurology 70, 1967–1971.
Chan, H. Y., Warrick, J. M., Andriola, I.,
Merry, D., and Bonini, N. M. (2002).
Genetic modulation of polygluta-
mine toxicity by protein conjugation
pathways in Drosophila. Hum. Mol.
Genet. 11, 2895–2904.
Chevalier-Larsen, E. S., and Merry, D. E.
(2012). Testosterone treatment fails
to accelerate disease in a transgenic
mouse model of spinal and bulbar
muscular atrophy. Dis. Model Mech.
5, 141–145.
Chevalier-Larsen, E. S., O’Brien, C. J.,
Wang, H., Jenkins, S. C., Holder,
L., Lieberman, A. P., et al. (2004).
Castration restores function and
neurofilament alterations of aged
symptomatic males in a transgenic
mouse model of spinal and bulbar
muscular atrophy. J. Neurosci. 24,
4778–4786.
Chymkowitch, P., Le May, N., Charneau,
P., Compe, E., and Egly, J. M.
(2011). The phosphorylation of the
androgen receptor by TFIIH directs
the ubiquitin/proteasome process.
EMBO J. 30, 468–479.
Ciechanover, A., and Brundin, P. (2003).
The ubiquitin proteasome system in
neurodegenerative diseases: some-
times the chicken, sometimes the
egg. Neuron 40, 427–446.
Coffey, K., and Robson, C. N. (2012).
Regulation of the androgen receptor
by post-translational modifications.
J. Endocrinol. 215, 221–237.
Davies, P., Watt, K., Kelly, S. M., Clark,
C., Price, N. C., and McEwan, I.
J. (2008). Consequences of poly-
glutamine repeat length for the
conformation and folding of the
androgen receptor amino-terminal
domain. J. Mol. Endocrinol. 41,
301–314.
Dejager, S., Bry-Gauillard, H., Bruck-
ert, E., Eymard, B., Salachas, F.,
LeGuern, E., et al. (2002). A com-
prehensive endocrine description of
Kennedy’s disease revealing andro-
gen insensitivity linked to CAG
repeat length. J. Clin. Endocrinol.
Metab. 87, 3893–3901.
Dong, X., Sweet, J., Challis, J. R., Brown,
T., and Lye, S. J. (2007). Transcrip-
tional activity of androgen receptor
is modulated by two RNA splicing
factors, PSF and p54nrb. Mol. Cell.
Biol. 27, 4863–4875.
Fargo, K. N., Galbiati, M., Foecking,
E. M., Poletti, A., and Jones, K.
J. (2008). Androgen regulation of
axon growth and neurite extension
in motoneurons. Horm. Behav. 53,
716–728.
Figiel, M., Szlachcic, W. J., Switonski, P.
M., Gabka, A., and Krzyzosiak, W. J.
(2012). Mouse models of polygluta-
mine diseases: review and data table.
Part I. Mol. Neurobiol. 46, 393–429.
Finsterer, J. (2009). Bulbar and spinal
muscular atrophy (Kennedy’s dis-
ease): a review. Eur. J. Neurol. 16,
556–561.
Finsterer, J. (2010). Perspectives of
Kennedy’s disease. J. Neurol. Sci. 298,
1–10.
Fischbeck, K. H. (2012). Developing
treatment for spinal and bulbar
muscular atrophy. Prog. Neurobiol.
99, 257–261.
Foradori, C. D., Weiser, M. J., and
Handa, R. J. (2008). Non-genomic
actions of androgens. Front. Neu-
roendocrinol. 29, 169–181.
Fratta, P., Malik, B., Gray, A., La Spada,
A. R., Hanna, M. G., Fisher, E. M.,
et al. (2013). FUS is not dysregu-
lated by the spinal bulbar muscular
atrophy androgen receptor polyglu-
tamine repeat expansion. Neurobiol.
Aging 34, e1517–1519.
Fu, M., Liu, M., Sauve, A. A., Jiao, X.,
Zhang, X., Wu, X., et al. (2006). Hor-
monal control of androgen receptor
function through SIRT1. Mol. Cell.
Biol. 26, 8122–8135.
Funderburk, S. F., Shatkina, L., Mink, S.,
Weis, Q., Weg-Remers, S., and Cato,
A. C. (2009). Specific N-terminal
mutations in the human androgen
receptor induce cytotoxicity. Neuro-
biol. Aging 30, 1851–1864.
Gaspar, M. L., Meo, T., Bourgarel,
P., Guenet, J. L., and Tosi, M.
(1991). A single base deletion in the
Tfm androgen receptor gene cre-
ates a short-lived messenger RNA
that directs internal translation ini-
tiation. Proc. Natl. Acad. Sci. U.S.A.
88, 8606–8610.
Gavrilova-Jordan, L. P., and Price, T. M.
(2007). Actions of steroids in mito-
chondria. Semin. Reprod. Med. 25,
154–164.
Gioeli, D., and Paschal, B. M. (2012).
Post-translational modification of
the androgen receptor. Mol. Cell.
Endocrinol. 352, 70–78.
Gottlieb, B., Beitel, L. K., Nadarajah, A.,
Paliouras, M., and Trifiro, M. (2012).
The androgen receptor gene muta-
tions database: 2012 update. Hum.
Mutat. 33, 887–894.
Gottlieb, B., Beitel, L. K., Wu, J. H.,
and Trifiro, M. (2004). The andro-
gen receptor gene mutations data-
base (ARDB): 2004 update. Hum.
Mutat. 23, 527–533.
Greene, L. A., and Tischler, A. S. (1976).
Establishment of a noradrenergic
clonal line of rat adrenal pheochro-
mocytoma cells which respond to
nerve growth factor. Proc. Natl. Acad.
Sci. U.S.A. 73, 2424–2428.
Guyenet, S. J., and La Spada, A. R.
(2006). “Triplet Repeat Diseases,” in
Encyclopedia of Molecular Cell Biol-
ogy and Molecular Medicine, 2nd
Edn. Weinheim: Wiley-VCH Verlag
GmbH & Co. KGaA.
He, B., Bai, S., Hnat, A. T., Kalman, R.
I., Minges, J. T., Patterson, C., et al.
(2004). An androgen receptor NH2-
terminal conserved motif interacts
with the COOH terminus of the
Hsp70-interacting protein (CHIP).
J. Biol. Chem. 279, 30643–30653.
He, B., Lee, L. W., Minges, J. T.,
and Wilson, E. M. (2002). Depen-
dence of selective gene activation
on the androgen receptor NH2- and
COOH-terminal interaction. J. Biol.
Chem. 277, 25631–25639.
Ikenaka, K., Katsuno, M., Kawai,
K., Ishigaki, S., Tanaka, F., and
Sobue, G. (2012). Disruption of
axonal transport in motor neu-
ron diseases. Int. J. Mol. Sci. 13,
1225–1238.
Jochum, T., Ritz, M. E., Schuster, C.,
Funderburk, S. F., Jehle, K., Schmitz,
K., et al. (2012). Toxic and non-
toxic aggregates from the SBMA and
normal forms of androgen recep-
tor have distinct oligomeric struc-
tures. Biochim. Biophys. Acta 1822,
1070–1078.
Johansen, J. A., Troxell-Smith, S. M., Yu,
Z., Mo, K., Monks, D. A., Lieber-
man, A. P., et al. (2011). Prenatal flu-
tamide enhances survival in a myo-
genic mouse model of spinal bul-
bar muscular atrophy. Neurodegener.
Dis. 8, 25–34.
Johansen, J. A., Yu, Z., Mo, K., Monks,
D. A., Lieberman, A. P., Breedlove,
S. M., et al. (2009). Recovery of
function in a myogenic mouse
model of spinal bulbar muscu-
lar atrophy. Neurobiol. Dis. 34,
113–120.
Jordan, C. L., and Doncarlos, L. (2008).
Androgens in health and disease: an
overview. Horm. Behav. 53, 589–595.
Jordan, C. L., and Lieberman, A. P.
(2008). Spinal and bulbar muscu-
lar atrophy: a motoneuron or muscle
disease? Curr. Opin. Pharmacol. 8,
752–758.
Katsuno, M., Adachi, H., Kume, A., Li,
M., Nakagomi, Y., Niwa, H., et al.
(2002). Testosterone reduction pre-
vents phenotypic expression in a
transgenic mouse model of spinal
and bulbar muscular atrophy. Neu-
ron 35, 843–854.
Katsuno, M., Adachi, H., Minamiyama,
M., Waza, M., Doi, H., Kondo, N.,
et al. (2010a). Disrupted transform-
ing growth factor-beta signaling in
spinal and bulbar muscular atrophy.
J. Neurosci. 30, 5702–5712.
www.frontiersin.org May 2013 | Volume 4 | Article 53 | 13
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Beitel et al. Polyglutamine-expanded AR dysfunction in SBMA
Katsuno, M., Banno, H., Suzuki, K.,
Adachi, H., Tanaka, F., and Sobue, G.
(2010b). Clinical features and mole-
cular mechanisms of spinal and bul-
bar muscular atrophy (SBMA). Adv.
Exp. Med. Biol. 685, 64–74.
Katsuno, M., Adachi, H., Minamiyama,
M., Waza, M., Tokui, K., Banno, H.,
et al. (2006). Reversible disruption
of dynactin 1-mediated retrograde
axonal transport in polyglutamine-
induced motor neuron degenera-
tion. J. Neurosci. 26, 12106–12117.
Katsuno, M., Sang, C., Adachi, H.,
Minamiyama, M., Waza, M., Tanaka,
F., et al. (2005). Pharmacological
induction of heat-shock proteins
alleviates polyglutamine-mediated
motor neuron disease. Proc. Natl.
Acad. Sci. U.S.A. 102, 16801–16806.
Katsuno, M., Tanaka, F., Adachi, H.,
Banno, H., Suzuki, K., Watanabe,
H., et al. (2012). Pathogenesis and
therapy of spinal and bulbar muscu-
lar atrophy (SBMA). Prog. Neurobiol.
99, 246–256.
Kazemi-Esfarjani, P., Trifiro, M. A.,
and Pinsky, L. (1995). Evidence
for a repressive function of the
long polyglutamine tract in the
human androgen receptor: possi-
ble pathogenetic relevance for the
(CAG)n-expanded neuronopathies.
Hum. Mol. Genet. 4, 523–527.
Kemp, M. Q., Poort, J. L., Baqri, R.
M., Lieberman, A. P., Breedlove,
S. M., Miller, K. E., et al. (2011).
Impaired motoneuronal retrograde
transport in two models of SBMA
implicates two sites of andro-
gen action. Hum. Mol. Genet. 20,
4475–4490.
La Spada, A. R., and Taylor, J. P. (2010).
Repeat expansion disease: progress
and puzzles in disease pathogenesis.
Nat. Rev. Genet. 11, 247–258.
La Spada, A. R., Wilson, E. M., Lubahn,
D. B., Harding, A. E., and Fis-
chbeck, K. H. (1991). Androgen
receptor gene mutations in X-linked
spinal and bulbar muscular atrophy.
Nature 352, 77–79.
LaFevre-Bernt, M. A., and Ellerby, L.
M. (2003). Kennedy’s disease. Phos-
phorylation of the polyglutamine-
expanded form of androgen recep-
tor regulates its cleavage by caspase-
3 and enhances cell death. J. Biol.
Chem. 278, 34918–34924.
Li, M., Chevalier-Larsen, E. S., Merry, D.
E., and Diamond, M. I. (2007). Sol-
uble androgen receptor oligomers
underlie pathology in a mouse
model of spinobulbar muscu-
lar atrophy. J. Biol. Chem. 282,
3157–3164.
Li, M., Miwa, S., Kobayashi, Y., Merry,
D. E., Yamamoto, M., Tanaka, F., et
al. (1998). Nuclear inclusions of the
androgen receptor protein in spinal
and bulbar muscular atrophy. Ann.
Neurol. 44, 249–254.
Li, X., Li, H., and Li, X. J. (2008). Intra-
cellular degradation of misfolded
proteins in polyglutamine neurode-
generative diseases. Brain Res. Rev.
59, 245–252.
Lieberman, A. P., Harmison, G., Strand,
A. D., Olson, J. M., and Fischbeck,
K. H. (2002). Altered transcrip-
tional regulation in cells expressing
the expanded polyglutamine andro-
gen receptor. Hum. Mol. Genet. 11,
1967–1976.
Lin, H. K., Wang, L., Hu, Y. C.,
Altuwaijri, S., and Chang, C.
(2002). Phosphorylation-dependent
ubiquitylation and degradation of
androgen receptor by Akt require
Mdm2 E3 ligase. EMBO J. 21,
4037–4048.
Lin, H. K., Yeh, S., Kang, H. Y.,
and Chang, C. (2001). Akt sup-
presses androgen-induced apoptosis
by phosphorylating and inhibiting
androgen receptor. Proc. Natl. Acad.
Sci. U.S.A. 98, 7200–7205.
MacLean, H. E., Chiu,W. S., Notini,A. J.,
Axell, A. M., Davey, R. A., McManus,
J. F., et al. (2008). Impaired skeletal
muscle development and function
in male, but not female, genomic
androgen receptor knockout mice.
FASEB J. 22, 2676–2689.
Malik, B., Nirmalananthan, N., Bilsland,
L. G., La Spada, A. R., Hanna, M. G.,
Schiavo, G., et al. (2011). Absence of
disturbed axonal transport in spinal
and bulbar muscular atrophy. Hum.
Mol. Genet. 20, 1776–1786.
Malik, B., Nirmalananthan, N., Gray,
A. L., La Spada, A. R., Hanna,
M. G., and Greensmith, L. (2013).
Co-induction of the heat shock
response ameliorates disease pro-
gression in a mouse model of human
spinal and bulbar muscular atrophy:
implications for therapy. Brain 136,
926–943.
Mandrusiak, L. M., Beitel, L. K., Wang,
X., Scanlon, T. C., Chevalier-
Larsen, E., Merry, D. E., et
al. (2003). Transglutaminase
potentiates ligand-dependent pro-
teasome dysfunction induced by
polyglutamine-expanded androgen
receptor. Hum. Mol. Genet. 12,
1497–1506.
Marron, T. U., Guerini, V., Rusmini,
P., Sau, D., Brevini, T. A., Martini,
L., et al. (2005). Androgen-induced
neurite outgrowth is mediated by
neuritin in motor neurones. J. Neu-
rochem. 92, 10–20.
McCampbell, A., Taylor, J. P., Taye, A.
A., Robitschek, J., Li, M., Walcott,
J., et al. (2000). CREB-binding
protein sequestration by expanded
polyglutamine. Hum. Mol. Genet. 9,
2197–2202.
McManamny, P., Chy, H. S., Finkelstein,
D. I., Craythorn, R. G., Crack, P.
J., Kola, I., et al. (2002). A mouse
model of spinal and bulbar muscu-
lar atrophy. Hum. Mol. Genet. 11,
2103–2111.
Merry, D. E. (2005). Animal mod-
els of Kennedy disease. NeuroRx 2,
471–479.
Merry, D. E., Kobayashi, Y., Bailey, C.
K., Taye, A. A., and Fischbeck, K.
H. (1998). Cleavage,aggregation and
toxicity of the expanded androgen
receptor in spinal and bulbar mus-
cular atrophy. Hum. Mol. Genet. 7,
693–701.
Minamiyama, M., Katsuno, M., Adachi,
H., Doi, H., Kondo, N., Iida, M.,
et al. (2012). Naratriptan mitigates
CGRP1-associated motor neuron
degeneration caused by an expanded
polyglutamine repeat tract. Nat.
Med. 18, 1531–1538.
Mitchell, J. D., and Borasio,G. D. (2007).
Amyotrophic lateral sclerosis. Lancet
369, 2031–2041.
Miyazaki, Y., Adachi, H., Katsuno, M.,
Minamiyama, M., Jiang, Y. M.,
Huang, Z., et al. (2012). Viral deliv-
ery of miR-196a ameliorates the
SBMA phenotype via the silencing
of CELF2. Nat. Med. 18, 1136–1141.
Mo, K., Razak, Z., Rao, P., Yu,
Z., Adachi, H., Katsuno, M., et
al. (2010). Microarray analysis of
gene expression by skeletal mus-
cle of three mouse models of
Kennedy disease/spinal bulbar mus-
cular atrophy. PLoS ONE 5:e12922.
doi:10.1371/journal.pone.0012922
Monks, D. A., Johansen, J. A., Mo,
K., Rao, P., Eagleson, B., Yu, Z., et
al. (2007). Overexpression of wild-
type androgen receptor in muscle
recapitulates polyglutamine disease.
Proc. Natl. Acad. Sci. U.S.A. 104,
18259–18264.
Monks, D. A., Rao, P., Mo, K., Johansen,
J. A., Lewis, G., and Kemp, M.
Q. (2008). Androgen receptor and
Kennedy disease/spinal bulbar mus-
cular atrophy. Horm. Behav. 53,
729–740.
Montie, H. L., Cho, M. S., Holder, L.,
Liu, Y., Tsvetkov, A. S., Finkbeiner, S.,
et al. (2009). Cytoplasmic retention
of polyglutamine-expanded andro-
gen receptor ameliorates disease via
autophagy in a mouse model of
spinal and bulbar muscular atrophy.
Hum. Mol. Genet. 18, 1937–1950.
Montie, H. L., and Merry, D. E. (2009).
Autophagy and access: understand-
ing the role of androgen receptor
subcellular localization in SBMA.
Autophagy 5, 1194–1197.
Montie, H. L., Pestell, R. G., and Merry,
D. E. (2011). SIRT1 modulates
aggregation and toxicity through
deacetylation of the androgen recep-
tor in cell models of SBMA. J. Neu-
rosci. 31, 17425–17436.
Morfini, G., Pigino, G., Szebenyi, G.,
You, Y., Pollema, S., and Brady, S.
T. (2006). JNK mediates pathogenic
effects of polyglutamine-expanded
androgen receptor on fast axonal
transport. Nat. Neurosci. 9, 907–916.
Morfini, G. A., Burns, M., Binder, L. I.,
Kanaan, N. M., LaPointe, N., Bosco,
D. A., et al. (2009). Axonal transport
defects in neurodegenerative dis-
eases. J. Neurosci. 29, 12776–12786.
Morishima, Y., Wang, A. M., Yu, Z.,
Pratt, W. B., Osawa, Y., and Lieber-
man, A. P. (2008). CHIP deletion
reveals functional redundancy of
E3 ligases in promoting degrada-
tion of both signaling proteins and
expanded glutamine proteins. Hum.
Mol. Genet. 17, 3942–3952.
Mukherjee, S., Thomas, M., Dadgar,
N., Lieberman, A. P., and Iniguez-
Lluhi, J. A. (2009). Small ubiquitin-
like modifier (SUMO) modifica-
tion of the androgen receptor
attenuates polyglutamine-mediated
aggregation. J. Biol. Chem. 284,
21296–21306.
Murata, T., Suzuki, E., Ito, S., Sawatsub-
ashi, S., Zhao, Y., Yamagata, K., et al.
(2008). RNA-binding protein hoip
accelerates polyQ-induced neurode-
generation in Drosophila. Biosci.
Biotechnol. Biochem. 72, 2255–2261.
Nedelsky, N. B., Pennuto, M., Smith, R.
B., Palazzolo, I., Moore, J., Nie, Z.,
et al. (2010). Native functions of the
androgen receptor are essential to
pathogenesis in a Drosophila model
of spinobulbar muscular atrophy.
Neuron 67, 936–952.
Orr, C. R., Montie, H. L., Liu,Y., Bolzoni,
E., Jenkins, S. C., Wilson, E. M., et al.
(2010). An interdomain interaction
of the androgen receptor is required
for its aggregation and toxicity in
spinal and bulbar muscular atrophy.
J. Biol. Chem. 285, 35567–35577.
Orr, H. T., and Zoghbi, H. Y.
(2007). Trinucleotide repeat dis-
orders. Annu. Rev. Neurosci. 30,
575–621.
Palazzolo, I., Burnett, B. G., Young,
J. E., Brenne, P. L., La Spada, A.
R., Fischbeck, K. H., et al. (2007).
Akt blocks ligand binding and pro-
tects against expanded polygluta-
mine androgen receptor toxicity.
Hum. Mol. Genet. 16, 1593–1603.
Palazzolo, I., Gliozzi, A., Rusmini, P.,
Sau, D., Crippa, V., Simonini, F., et
Frontiers in Neurology | Neurodegeneration May 2013 | Volume 4 | Article 53 | 14
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Beitel et al. Polyglutamine-expanded AR dysfunction in SBMA
al. (2008). The role of the polyglu-
tamine tract in androgen receptor.
J. Steroid Biochem. Mol. Biol. 108,
245–253.
Palazzolo, I., Nedelsky, N. B., Askew,
C. E., Harmison, G. G., Kasantsev,
A. G., Taylor, J. P., et al. (2010). B2
attenuates polyglutamine-expanded
androgen receptor toxicity in cell
and fly models of spinal and bulbar
muscular atrophy. J. Neurosci. Res.
88, 2207–2216.
Palazzolo, I., Stack, C., Kong, L., Musaro,
A., Adachi, H., Katsuno, M., et al.
(2009). Overexpression of IGF-1 in
muscle attenuates disease in a mouse
model of spinal and bulbar muscular
atrophy. Neuron 63, 316–328.
Paliouras, M., Zaman, N., Lumbroso,
R., Kapogeorgakis, L., Beitel, L. K.,
Wang, E., et al. (2011). Dynamic
rewiring of the androgen receptor
protein interaction network corre-
lates with prostate cancer clinical
outcomes. Integr. Biol. (Camb.) 3,
1020–1032.
Pandey, U. B., Batlevi, Y., Baehrecke, E.
H., and Taylor, J. P. (2007a). HDAC6
at the intersection of autophagy, the
ubiquitin-proteasome system and
neurodegeneration. Autophagy 3,
643–645.
Pandey, U. B., Nie, Z., Batlevi, Y.,
McCray, B. A., Ritson, G. P., Nedel-
sky, N. B., et al. (2007b). HDAC6
rescues neurodegeneration and pro-
vides an essential link between
autophagy and the UPS. Nature 447,
859–863.
Parboosingh, J. S., Figlewicz, D. A.,
Krizus, A., Meininger, V., Azad, N.
A., Newman, D. S., et al. (1997).
Spinobulbar muscular atrophy can
mimic ALS: the importance of
genetic testing in male patients
with atypical ALS. Neurology 49,
568–572.
Parodi, S., and Pennuto, M. (2011).
Neurotoxic effects of androgens in
spinal and bulbar muscular atrophy.
Front. Neuroendocrinol. 32, 416–425.
Pennuto, M., and Fischbeck, K. H.
(2010). “Therapeutic Prospects for
Polyglutamine Disease,” in Protein
Misfolding Diseases: Current and
Emerging Principles and Therapies,
eds M. Ramirez-Alvarado, J. W.
Kelly, and C. M. Dobson (Hoboken:
John Wiley & Sons, Inc.), 887–902.
Piccioni, F., Pinton, P., Simeoni, S.,
Pozzi, P., Fascio, U., Vismara, G., et
al. (2002). Androgen receptor with
elongated polyglutamine tract forms
aggregates that alter axonal traffick-
ing and mitochondrial distribution
in motor neuronal processes. FASEB
J. 16, 1418–1420.
Poletti, A. (1999). CAG Expansion in
androgen receptor gene and neu-
ronal cell death. Rec. Res. Dev. Neu-
rochem. 2, 507–515.
Qiang, Q., Adachi, H., Huang, Z., Jiang,
Y. M., Katsuno, M., Minamiyama,
M., et al. (2013). Genistein, a nat-
ural product derived from soy-
beans, ameliorates polyglutamine-
mediated motor neuron disease. J.
Neurochem. doi:10.1111/jnc.12172.
[Epub ahead of print].
Ranganathan, S., and Fischbeck, K. H.
(2010). Therapeutic approaches to
spinal and bulbar muscular atrophy.
Trends Pharmacol. Sci. 31, 523–527.
Ranganathan, S., Harmison, G. G.,
Meyertholen, K., Pennuto, M., Bur-
nett, B. G., and Fischbeck, K. H.
(2009). Mitochondrial abnormali-
ties in spinal and bulbar muscular
atrophy. Hum. Mol. Genet. 18,27–42.
Reichow, S. L., Hamma, T., Ferre-
D’Amare, A. R., and Varani, G.
(2007). The structure and func-
tion of small nucleolar ribonucle-
oproteins. Nucleic Acids Res. 35,
1452–1464.
Rhodes, L. E., Freeman, B. K., Auh, S.,
Kokkinis, A. D., La Pean, A., Chen,
C., et al. (2009). Clinical features of
spinal and bulbar muscular atrophy.
Brain 132, 3242–3251.
Rinaldi, C., Bott, L. C., Chen, K.
L., Harmison, G. G., Katsuno, M.,
Sobue, G., et al. (2012). Insulin like
growth factor (IGF)-1 administra-
tion ameliorates disease manifesta-
tions in a mouse model of spinal and
bulbar muscular atrophy. Mol. Med.
18, 1261–1268.
Rocchi, A., and Pennuto, M. (2013).
New routes to therapy for spinal
and bulbar muscular atrophy. J. Mol.
Neurosci. PMID:23420040. [Epub
ahead of print].
Ross, C. A. (1995). When more is less:
pathogenesis of glutamine repeat
neurodegenerative diseases. Neuron
15, 493–496.
Ross, R. A., Spengler, B. A., and Biedler,
J. L. (1983). Coordinate morpho-
logical and biochemical interconver-
sion of human neuroblastoma cells.
J. Natl. Cancer Inst. 71, 741–747.
Rubinsztein, D. C. (2006). The roles of
intracellular protein-degradation
pathways in neurodegeneration.
Nature 443, 780–786.
Rusmini, P., Bolzoni, E., Crippa, V.,
Onesto, E., Sau, D., Galbiati, M., et al.
(2010). Proteasomal and autophagic
degradative activities in spinal and
bulbar muscular atrophy. Neurobiol.
Dis. 40, 361–369.
Rusmini, P., Sau, D., Crippa, V., Palaz-
zolo, I., Simonini, F., Onesto, E., et
al. (2007). Aggregation and protea-
some: the case of elongated polyg-
lutamine aggregation in spinal and
bulbar muscular atrophy. Neurobiol.
Aging 28, 1099–1111.
Rusmini, P., Simonini, F., Crippa, V.,
Bolzoni, E., Onesto, E., Cagnin,
M., et al. (2011). 17-AAG increases
autophagic removal of mutant
androgen receptor in spinal and
bulbar muscular atrophy. Neurobiol.
Dis. 41, 83–95.
Sau, D., Rusmini, P., Crippa, V., Onesto,
E., Bolzoni, E., Ratti, A., et al. (2011).
Dysregulation of axonal transport
and motorneuron diseases. Biol. Cell
103, 87–107.
Schiffer, N. W., Ceraline, J., Hartl, F.
U., and Broadley, S. A. (2008). N-
terminal polyglutamine-containing
fragments inhibit androgen recep-
tor transactivation function. Biol.
Chem. 389, 1455–1466.
Schindler, M., Fabre, C., de Weille,
J., Carreau, S., Mersel, M., and
Bakalara, N. (2012). Disruption of
nongenomic testosterone signaling
in a model of spinal and bulbar mus-
cular atrophy. Mol. Endocrinol. 26,
1102–1116.
Shao, J., Welch, W. J., Diprospero, N. A.,
and Diamond, M. I. (2008). Phos-
phorylation of profilin by ROCK1
regulates polyglutamine aggrega-
tion. Mol. Cell. Biol. 28, 5196–5208.
Solakidi, S., Psarra, A. M., Nikolaropou-
los, S., and Sekeris, C. E. (2005).
Estrogen receptors alpha and beta
(ERalpha and ERbeta) and andro-
gen receptor (AR) in human sperm:
localization of ERbeta and AR in
mitochondria of the midpiece. Hum.
Reprod. 20, 3481–3487.
Sopher, B. L., Thomas, P. S. Jr., LaFevre-
Bernt, M. A., Holm, I. E.,Wilke, S. A.,
Ware, C. B., et al. (2004). Androgen
receptor YAC transgenic mice reca-
pitulate SBMA motor neuronopa-
thy and implicate VEGF164 in the
motor neuron degeneration. Neuron
41, 687–699.
Stenoien, D. L., Cummings, C. J.,
Adams, H. P., Mancini, M. G.,
Patel, K., DeMartino, G. N., et
al. (1999). Polyglutamine-expanded
androgen receptors form aggregates
that sequester heat shock proteins,
proteasome components and SRC-
1, and are suppressed by the HDJ-
2 chaperone. Hum. Mol. Genet. 8,
731–741.
Su, S., Jou, S., Cheng, W., Lin, T., Li, J.,
Huang, C., et al. (2010). Mitochon-
drial DNA damage in spinal and
bulbar muscular atrophy patients
and carriers. Clin. Chim. Acta 411,
626–630.
Suzuki, E., Zhao, Y., Ito, S., Sawatsub-
ashi, S., Murata, T., Furutani, T., et al.
(2009). Aberrant E2F activation by
polyglutamine expansion of andro-
gen receptor in SBMA neurotoxic-
ity. Proc. Natl. Acad. Sci. U.S.A. 106,
3818–3822.
Szebenyi, G., Morfini, G. A., Bab-
cock, A., Gould, M., Selkoe, K.,
Stenoien, D. L., et al. (2003).
Neuropathogenic forms of hunt-
ingtin and androgen receptor inhibit
fast axonal transport. Neuron 40,
41–52.
Takahashi, T., Katada, S., and Onodera,
O. (2010). Polyglutamine diseases:
where does toxicity come from? what
is toxicity? where are we going? J.
Mol. Cell Biol. 2, 180–191.
Takeyama, K., Ito, S., Yamamoto,
A., Tanimoto, H., Furutani, T.,
Kanuka, H., et al. (2002). Androgen-
dependent neurodegeneration by
polyglutamine-expanded human
androgen receptor in Drosophila.
Neuron 35, 855–864.
Tanaka, F., Katsuno, M., Banno, H.,
Suzuki, K., Adachi, H., and Sobue,
G. (2012). Current status of treat-
ment of spinal and bulbar mus-
cular atrophy. Neural Plast. 2012,
369284.
Taylor, J. P., Tanaka, F., Robitschek, J.,
Sandoval, C. M., Taye, A., Markovic-
Plese, S., et al. (2003). Aggre-
somes protect cells by enhancing the
degradation of toxic polyglutamine-
containing protein. Hum. Mol.
Genet. 12, 749–757.
Thomas, M., Harrell, J. M., Mor-
ishima, Y., Peng, H. M., Pratt, W.
B., and Lieberman, A. P. (2006a).
Pharmacologic and genetic inhibi-
tion of hsp90-dependent trafficking
reduces aggregation and promotes
degradation of the expanded glu-
tamine androgen receptor without
stress protein induction. Hum. Mol.
Genet. 15, 1876–1883.
Thomas, P. S. Jr., Fraley, G. S., Damian,
V., Woodke, L. B., Zapata, F., Sopher,
B. L., et al. (2006b). Loss of endoge-
nous androgen receptor protein
accelerates motor neuron degen-
eration and accentuates androgen
insensitivity in a mouse model of
X-linked spinal and bulbar muscu-
lar atrophy. Hum. Mol. Genet. 15,
2225–2238.
Tokui, K., Adachi, H., Waza, M., Kat-
suno, M., Minamiyama, M., Doi, H.,
et al. (2009). 17-DMAG ameliorates
polyglutamine-mediated motor
neuron degeneration through well-
preserved proteasome function in
an SBMA model mouse. Hum. Mol.
Genet. 18, 898–910.
www.frontiersin.org May 2013 | Volume 4 | Article 53 | 15
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Beitel et al. Polyglutamine-expanded AR dysfunction in SBMA
Trifiro, M. A., Kazemi-Esfarjani, P., and
Pinsky, L. (1994). X-linked muscu-
lar atrophy and the androgen recep-
tor. Trends Endocrinol. Metab. 5,
416–421.
Truant, R., Raymond, L. A., Xia, J.,
Pinchev, D., Burtnik, A., and Atwal,
R. S. (2006). Canadian Association
of Neurosciences Review: polyglu-
tamine expansion neurodegenera-
tive diseases. Can. J. Neurol. Sci. 33,
278–291.
Vismara, G., Simonini, F., Onesto, E.,
Bignamini, M., Miceli, V., Martini,
L., et al. (2009). Androgens inhibit
androgen receptor promoter activa-
tion in motor neurons. Neurobiol.
Dis. 33, 395–404.
Walcott, J. L., and Merry, D. E. (2002).
Trinucleotide repeat disease. The
androgen receptor in spinal and bul-
bar muscular atrophy. Vitam. Horm.
65, 127–147.
Wang, A. M., Miyata, Y., Klinedinst,
S., Peng, H. M., Chua, J. P.,
Komiyama, T., et al. (2013). Activa-
tion of Hsp70 reduces neurotoxicity
by promoting polyglutamine pro-
tein degradation. Nat. Chem. Biol. 9,
112–118.
Wang, A. M., Morishima, Y., Clapp, K.
M., Peng, H. M., Pratt, W. B., Gest-
wicki, J. E., et al. (2010). Inhibi-
tion of hsp70 by methylene blue
affects signaling protein function
and ubiquitination and modulates
polyglutamine protein degradation.
J. Biol. Chem. 285, 15714–15723.
Waza, M., Adachi, H., Katsuno,
M., Minamiyama, M., Sang, C.,
Tanaka, F., et al. (2005). 17-AAG,
an Hsp90 inhibitor, ameliorates
polyglutamine-mediated motor
neuron degeneration. Nat. Med. 11,
1088–1095.
Xiao, H., Yu, Z., Wu, Y., Nan, J., Merry,
D. E., Sekiguchi, J. M., et al. (2012).
A polyglutamine expansion disease
protein sequesters PTIP to attenuate
DNA repair and increase genomic
instability. Hum. Mol. Genet. 21,
4225–4236.
Xu, K., Shimelis, H., Linn, D. E., Jiang,
R., Yang, X., Sun, F., et al. (2009).
Regulation of androgen receptor
transcriptional activity and speci-
ficity by RNF6-induced ubiquitina-
tion. Cancer Cell 15, 270–282.
Yamamoto, M., Mitsuma, N., Inukai,
A., Ito, Y., Li, M., Mitsuma, T.,
et al. (1999). Expression of GDNF
and GDNFR-alpha mRNAs in mus-
cles of patients with motor neu-
ron diseases. Neurochem. Res. 24,
785–790.
Yang, Z., Chang, Y. J., Yu, I. C.,
Yeh, S., Wu, C. C., Miyamoto, H.,
et al. (2007). ASC-J9 ameliorates
spinal and bulbar muscular atro-
phy phenotype via degradation of
androgen receptor. Nat. Med. 13,
348–353.
Young, J. E., Garden, G. A., Martinez,
R. A., Tanaka, F., Sandoval, C.
M., Smith, A. C., et al. (2009).
Polyglutamine-expanded androgen
receptor truncation fragments
activate a Bax-dependent
apoptotic cascade mediated
by DP5/Hrk. J. Neurosci. 29,
1987–1997.
Yu, Z., Dadgar, N., Albertelli, M., Gruis,
K., Jordan, C., Robins, D. M., et
al. (2006a). Androgen-dependent
pathology demonstrates myopathic
contribution to the Kennedy dis-
ease phenotype in a mouse knock-
in model. J. Clin. Invest. 116,
2663–2672.
Yu, Z., Dadgar, N., Albertelli, M.,
Scheller, A., Albin, R. L., Robins,
D. M., et al. (2006b). Abnormal-
ities of germ cell maturation and
sertoli cell cytoskeleton in andro-
gen receptor 113 CAG knock-in
mice reveal toxic effects of the
mutant protein. Am. J. Pathol. 168,
195–204.
Yu, Z.,Wang,A. M.,Adachi, H., Katsuno,
M., Sobue, G., Yue, Z., et al. (2011).
Macroautophagy is regulated by the
UPR-mediator CHOP and accen-
tuates the phenotype of SBMA
mice. PLoS Genet. 7:e1002321.
doi:10.1371/journal.pgen.1002321
Yu, Z., Wang, A. M., Robins, D. M.,
and Lieberman, A. P. (2009). Altered
RNA splicing contributes to skeletal
muscle pathology in Kennedy dis-
ease knock-in mice. Dis. Model
Mech. 2, 500–507.
Conflict of Interest Statement: The
authors declare that the research was
conducted in the absence of any com-
mercial or financial relationships that
could be construed as a potential con-
flict of interest.
Received: 09 March 2013; accepted: 26
April 2013; published online: 15 May
2013.
Citation: Beitel LK, Alvarado C,
Mokhtar S, Paliouras M and Trifiro M
(2013) Mechanisms mediating spinal
and bulbar muscular atrophy: investi-
gations into polyglutamine-expanded
androgen receptor function and dys-
function. Front. Neurol. 4:53. doi:
10.3389/fneur.2013.00053
This article was submitted to Frontiers in
Neurodegeneration, a specialty of Fron-
tiers in Neurology.
Copyright © 2013 Beitel, Alvarado,
Mokhtar, Paliouras and Trifiro. This is
an open-access article distributed under
the terms of the Creative Commons Attri-
bution License, which permits use, distri-
bution and reproduction in other forums,
provided the original authors and source
are credited and subject to any copy-
right notices concerning any third-party
graphics etc.
Frontiers in Neurology | Neurodegeneration May 2013 | Volume 4 | Article 53 | 16
